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VI. SUMMARY
Lung cancer is the commonest cause of cancer related death in North America and 
Western Europe. It comprises of two subgroups, small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC).
Non-small cell lung cancer accounts for approximately three quarters of all patients 
presenting with lung cancer. The majority of patients present with advanced disease, 
survival is extremely poor with a median survival rate of 6 to 9 months. Many 
patients are unfit for radical treatments such as surgery / radiotherapy, and therefore 
receive palliative treatment only. Traditionally, selection of these patients for active 
or supportive treatment has been based on clinico-pathological criteria, including 
age, stage, performance status, weight loss or hypoalbuminaemia. Palliation of 
symptoms, improvement in patient’s quality of life and prolongation of survival are 
the main aims of treatment.
Various factors have been associated with the poor survival rates of patients with 
inoperable non-small cell lung cancer. These include stage of disease, performance 
status and loss of weight. In these patients, weight loss has been reported to be 
associated with either reduced energy intake or increased energy expenditure, or as a 
combination of both. The resultant negative energy balance leads to a loss of 
adipose tissue and protein mass, resulting in tissue wasting, reduced performance 
status and ultimately death. The reasons for the negative energy balance remain 
unclear. However, previous studies of advanced cancer have reported that various 
factors contribute to an increased resting energy expenditure including the presence
14
of a systemic inflammatory response, as evidenced by raised circulating 
concentrations of C-reactive protein. Therefore it may be that the presence of the 
systemic inflammatory response may be associated with poor survival.
The primary aim of this thesis was to assess the impact of the systemic inflammatory 
response on survival in patients with inoperable non-small cell lung cancer. In 
addition, an inflammation based prognostic score was constructed and evaluated.
Various studies have shown that a reduction in physical function, as assessed by 
performance status, was associated with loss of weight in patients with advanced 
cancer. A study of 50 patients with inoperable non-small cell lung cancer was 
undertaken to examine the relationship of ECOG performance status (ECOG-ps), 
anthropometric and blood parameters (including full blood count, white cell count, 
albumin concentration and C-reative protein). This study demonstrated that mid­
upper arm circumference was strongly associated with ECOG-ps in patients with 
inoperable non-small cell lung cancer. This study demonstrated that albumin 
concentrations were strongly associated with ECOG-ps.
Previous studies have proposed that the combination of albumin and C-reactive 
protein may form the basis of a useful standardised and non-subjective assessment of 
outcome in advanced cancer patients. The following studies compared the above 
combination with ECOG-ps and various haematological and biochemical factors in 
patients with inoperable NSCLC.
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A study of an unselected cohort of 161 patients with inoperable non-small cell lung 
cancer was performed to assess the value of combining C-reactive protein and 
recognised prognostic factors such as stage, performance status and hypoalbuminaemia 
to form new prognostic scores. The study demonstrated that both the established 
indicators of the presence of a systemic inflammatory response, white cell count and C- 
reactive protein, were predictive of survival in patients with inoperable NSCLC. This 
study also demonstrated that when C-reactive protein concentrations were combined 
with stage, ECOG-ps and albumin to form new prognostic scores, these combined 
scores improved the prediction of survival based on stage, ECOG-ps or albumin alone. 
Furthermore, the results of this study showed that a cumulative score based on C- 
reactive protein and albumin provides comparable prognostic information to that of 
stage and ECOG-ps. This cumulative score has the advantage of being simple to 
measure, routinely available and well standardised.
Following the construction of the cumulative prognostic score, the Glasgow 
Prognostic Score (GPS), the value of this score was assessed prospectively in 
patients receiving platinum based chemotherapy for inoperable non-small cell lung 
cancer. A total of 109 patients were included in the study. When the GPS was 
compared to ECOG-ps, the GPS was found to be superior to performance status in 
predicting outcome in patients receiving chemotherapy. This suggests that the GPS 
offers additional prognostic information and may be useful in the selection of 
patients with inoperable non-small cell lung cancer for chemotherapy.
Since the inflammation based prognostic score (GPS) was found to have a similar 
prognostic value to that of stage and performance status, and to be superior in
16
predicting survival in patients receiving platinum-based chemotherapy, a prospective 
study was undertaken to compare the reproducibility of the GPS and ECOG-ps in a 
second centre. Eighty seven patients with inoperable NSCLC were included. This 
study confirmed that the GPS was at least equivalent to that of ECOG performance 
status in predicting the survival of patients with inoperable NSCLC.
The previous study chapters have shown that the cumulative prognostic score based 
on C-reactive protein and albumin (GPS) has prognostic value, independent of 
performance status, in patients with NSCLC. In the final study chapter, the temporal 
changes in the GPS were compared with those of performance status in patients with 
inoperable NSCLC. The results of this study demonstrated that the components of 
the GPS were more sensitive indicators of disease progression than the GPS itself. 
This suggests that the GPS may require more refinement in order to improve the 
monitoring of disease progression in patents with inoperable NSCLC.
In conclusion, the work presented in this thesis suggests that the Glasgow Prognostic 
score may be useful in the assessment of patients with inoperable non-small cell lung 
cancer. Further work should be carried out to assess its value in other advanced 
cancers.
17
CHAPTER 1
1 INTRODUCTION AND AIMS
1.1 Incidence and mortality of lung cancer
World-wide, lung cancer is the commonest cause of cancer-related death, responsible 
for over 800,000 deaths each year (International Agency for Research on Cancer, 
2001). Recently, the incidence has been falling slightly amongst men, but rising 
considerably amongst women, and in some countries seems set to overtake breast 
cancer as the commonest cause of cancer related death in women (Boyle et al, 
2000). It has a greater global incidence than that of colorectal, cervical and breast 
cancer combined. It has been reported that lung cancer causes more than 1 million 
deaths world-wide; this global death rate has rose at 0.5% per annum since the 
1930’s (Souhami and Tobias 1998; Spiro and Porter, 2002). This is in contrast to 
other cancers which, in the developed nations, have shown a decline in death rates 
over the past 20 years (Devita et al, 1997).
In the European Community there are approximately 158,000 new patients with lung 
cancer registered each year. Forty thousand new cases of lung cancer are registered 
each year in the United Kingdom. Within the male population, this incidence has 
decreased over the past 20 years in line with a reduction in cigarette smoking in the 
Western World. However, a similar decline is not evident amongst females. Indeed 
the incidence rates in women are increasing at a rate similar to those seen 20 years 
ago in men (Splinter, 1997; Spiro and Porter, 2002). For example, in 1952 the male: 
female ratio for lung cancer was 13:1, however, more recently this has been reported 
to be 2:1 (Souhami and Tobias, 1998).
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In Scotland, in 1997, lung cancer was the most commonly diagnosed neoplasm in 
men comprising 22% of all cancer registrations. Whilst, in women, lung cancer was 
the second most commonly occurring cancer after breast cancer, comprising 14% of 
registrations (Harkness et al, 2002). The West of Scotland has the highest incidence 
rate of lung cancer in the world (De Vos Irvine et al, 1993). Within this population, 
Glasgow has the highest incidence rate, 30% above the Scottish average (Kesson et 
al, 1998).
Lung cancer is also responsible for a quarter of all cancer-related deaths (Thatcher 
and Spiro, 1994; Simmonds, 1999). In Scotland, lung cancer is the leading cause of 
cancer-related death, being ranked third overall behind ischaemic heart disease and 
cerebrovascular disease as the cause of death (Kesson et al, 1998; Scottish Cancer 
Intelligence Unit 2000).
Recent reports predicted, that deaths from lung cancer amongst women are set to 
overtake breast cancer as the leading cause of cancer-related death amongst women 
(Cote et al, 1998, Boyle et al, 2000). Indeed within the United Kingdom, it has 
recently been reported that mortality rates from lung cancer have now overtaken that 
of breast cancer, with lung cancer accounting for 18% and breast cancer accounting 
for 17% of cancer related deaths amongst women (2002, CRC Cancerstats, 
www.cancerresearchuk.org).
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1.2 Aetiology of lung cancer
1.2.1 Environmental factors related to lung cancer
Smoking is the major risk factor for lung cancer. Approximately 90% of all lung 
cancers result from smoking (Wingo et al, 1999). Small cell and squamous cell 
lung cancer have a particularly strong association with cigarette smoking: indeed 
only 1% of small cell lung cancers occur in non-smokers (Devita et al., 1997; Osann 
et al, 2000). Smoking at an early age appears to increase the susceptibility to this 
form of lung cancer. A study by Peto and co-workers (2000) showed that the 
cumulative risk of lung cancer amongst men who continued to smoke was 15.9% by 
75 years of age. For those who stopped smoking, the risks were 9.9%, 6%, 3% and 
1.7% for those who stopped at 60, 50, 40 and 30 years of age respectively. Peto and 
co-workers (2000) also demonstrated a similar pattern for women, the cumulative 
risk amongst women who continued to smoke at 75 years of age being 9.5%, 
compared with 5.3% and 2.2% amongst those women who had ceased smoking at 60 
and 50 years of age respectively. Passive smoking is also an important issue, as 17 
to 24% of lung cancer cases amongst non-smokers can be attributed to high levels of 
exposure to cigarette smoke during their childhood and adolescence (Devita et al, 
1997; Hackshaw et al, 1997).
The risk of developing lung cancer is also increased as a result of exposure to 
asbestos, radon, chloromethyl, polycyclic aromatic hydrocarbons, chromium, nickel, 
and inorganic arsenic compounds (Devita et al, 1997; Souhami and Tobias, 1998).
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The risk of developing lung cancer from asbestos is largely dependent on the 
intensity of the exposure; asbestos is thought to be responsible for 3 to 6% of all lung 
cancer deaths (De Vos Irvine et al, 1993; Devita et al, 1997). In the West of 
Scotland exposure to asbestos was traditionally associated with the shipbuilding 
industry on the River Clyde (Samet, 1993; De Vos Irvine et al, 1993); it also 
occurred in the insulation, boiler and cement industries.
Environmental pollution, in particular industrial pollutants, may also be considered 
as a causative factor of lung cancer. Various studies (Lloyd et al, 1985; Smith et al, 
1987) report that whilst foundry workers are more likely to develop lung cancer than 
other occupational groups, an association also exists between the industrial 
pollutants from the steel foundries and the lung cancer rates in the residential areas 
surrounding them. Gustavson and co-workers (2000) reported that occupational 
hazards (eg. aluminium production, arsenic, asbestos, bis-chloromethyl ether, 
beryllium, cadmium, hexavalent chromium, coke and coal gasification fumes, 
crystalline silica, nickel, radon and soot) also have a carcinogenic effect on human 
lung tissue. Nyberg and co-workers (2000) concluded that the incidence of lung 
cancer could be reduced if occupational exposure to diesel exhaust, asbestos, and 
combustion products were reduced to a “safe” level.
Therefore, if sufficient means were taken to reduce these multiple factors, then it 
may appear that lung cancer is largely a preventable disease (Splinter, 1997).
22
1.2.2 Genetic factors relating to lung cancer
Genetic predisposition has been reported to be a factor in the development of lung 
cancer. There is increasing evidence to suggest that the metabolites of carcinogens 
cause malignancy, and the metabolisms of these metabolites are genetically 
determined. In non-small cell lung cancer, mutation of the p53 gene (the tumour 
suppressor gene) may be correlated with exposure to tobacco smoke carcinogens. 
The role of the p53 gene is to maintain genomic integrity which may occur from 
DNA damage. It serves as a transcription factor to activate the expression of genes 
that control cell cycle checkpoints, apoptosis, DNA repair and angiogenesis. The 
p53 gene is the most frequently mutated tumour suppressor gene in human 
malignancies, affecting approximately 90% of small cell and 50% of non-small cell 
lung cancers. These mutations frequently occur in several types of non-small cell 
lung cancer, affecting approximately 51% of squamous cell and 54% of large cell 
carcinomas, but are less commonly observed in adenocarcinomas (Devita et al, 
2001; Mitsudomi et al, 2001; Ushijima et al, 2001).
The ras-family gene, composed of H-ras-I; K-ras and N-ras, can be activated to play 
a role in the development of cancer by point mutation. In non-small cell lung cancer, 
changes have been shown to exist in the single transduction of the K-ras gene. 
Mutation of this gene occurs in approximately 20% of non-small cell lung cancers. 
This mutation is commonly associated with adenocarcinoma (30%), and is less 
frequently seen (12%) in patients with squamous and large cell carcinoma (Johnson, 
1995).
23
Such genetic mutations may be useful as markers in future stratification for treatment 
and in the context of clinical trials (Johnston, 1995; Devita et al, 2001; Mitsudomi et 
al, 2001).
24
1.3 Pathology of lung cancer
In 1981,The World Health Organisation (WHO) developed a classification for lung 
cancer, and this is used world-wide to define tumour type (Turner-Warwick et al, 
1991; Devita et al, 1997)
I Benign
II Dysplasia and carcinoma in situ
III Malignant
A Squamous cell carcinoma (epidermoid and spindle cells)
B Small Cell Carcinoma
1. Oat Cell
2. Intermediate cell
3. Combined oat cell
C Adenocarcinoma
1. Acinar
2. Papillary
3. Bronchoalveolar
4. Mucus Secreting
D Large Cell Carcinoma
1. Giant Cell
2. Clear Cell
Figure 1.1 World Health Organisation Histological Classification of Epithelial 
Bronchogenic Carcinoma
Lung cancer can be divided into two broad categories; Small cell lung cancer 
(SCLC) and Non-small cell lung cancer (NSCLC). SCLC accounts for 
approximately 25% of all cases, whilst NSCLC accounts for 75% (Simmonds, 
1999).
1.3.1 Small cell lung cancer
SCLC was first recognised by Barnard in 1926. Prior to this it was regarded as an oat 
cell sarcoma of the mediastinum (Devita et al., 1997). This tumour is so termed 
because the nuclei are thought to resembie oat grains (see Figure 1.2).
u l  v J l  I L I I I *Ad a m
(www.mesotheliomamedical.com/images; www.willroberts.com/lungcancer)
Trachea
carcinoma
Small cell carcinoma consists of small cells with dense nuclei, their cytoplasm being 
very sparse with moulding of adjacent nuclei where the cells are in close contact 
with each other. They are derived from the Kulchitsky cells of the bronchial wall 
(Brewis, 1991), develop in cell clusters not following any pattern (Turner-Warwick 
et al., 1991, Chiti et al, 1999), and are characterised by a high mitotic rate, 
inconspicuous nuclei, finely granular (“salt and pepper”) nuclei, as well as the
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overall size of the cell. These cells are in general less than the diameter of three 
resting lymphocytes (Franklin, 2000).
In 1981, The World Health Organisation classified small cell lung cancer into three 
subtypes; oat cell or small cell undifferentiated, intermediate-cell type, and combined 
small cell carcinoma (Turner-Warwick et al, 1991; Devita et al., 1997). However, 
this classification has since been revised (Franklin, 2000), and these groups are now 
combined into one single category of small cell carcinoma.
Approximately 70% of all patients with small cell lung cancer present with extensive 
disease, and have evidence of metastatic spread at time of diagnosis, especially liver, 
adrenal, bone, bone marrow and brain (Hoffman et al, 2000). It has long been 
recognised that the number of metastatic sites is proportional to the extent of disease, 
resulting in a poorer prognosis. Moreover, liver and cerebral mestatases confer a 
significantly shorter survival compared with bone, soft tissue or bone marrow 
involvement. (Vincent et al, 1987; Elias, 1998; Chiti et al, 1999; Yip and Harper, 
2000).
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1.3.2 Non-small cell lung cancer
NSCLC accounts for approximately three quarters of all histological types of lung 
cancer related deaths world-wide (Hide and Minna, 1991; Hespanhol et al, 1995; 
Juretic et al., 1999; Ferrigno and Buccheri, 2000). It comprises several types, namely 
squamous cell carcinoma, adenocarcinoma and large cell, which account for 50%; 
30% and 20% respectively (Souhami and Tobias, 1998).
Squamous cell carcinoma
This is the commonest type of lung cancer, it is mostly found in men, and has been 
reported to have a strong association with cigarette smoking (Barbone et al., 1997; 
Kreuzer et al., 1999; Payne 2001). The tumour tends to arise most frequently in the 
proximal segmental bronchi, almost always growing from the hilum, and is 
associated with squamous metaplasia (see Figure 1.3).
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Figure 1.3 Squamous cell carcinoma of the lung
(www.nlm.nih.gov/medlineplus/encv/imagepages/18017.htm; 
www. wi 11 roberts. com/1 ungcancer)
These tumour cells are composed of epithelial cells, which may be either poorly or 
well differentiated and have a keratinised appearance (Devita et al., 1997).
In the early stages stratified squamous epithelium is replaced by malignant squamous 
cells without invasion through the basement membranes (Turner-Warwick et 
al., 1991; Devita et al., 1997, Chiti et al 1999). Squamous cell lung cancers may be 
detected at an early stage either by cytological or histopathological examination. 
Bronchoscopy remains the most frequent method of obtaining tissue for diagnosis. 
However, in certain situations bronchial biopsy is not possible as a result of an 
inaccessible site or if the patient is at risk of haemorrhage. In such instances
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cytopathology maybe used to obtain a tissue diagnosis via the sputum, washings or 
brushings obtained at the time of bronchoscopy (Piaton et al, 1995).
In the later stages squamous cell carcinomas of the lung may be found to invade the 
basement membranes, extend into the bronchial lumen and produce an obstruction 
which may result in atelectasis or pneumonia. At the time of diagnosis, 50% of 
cases have disease limited to the thorax, although mediastinal involvement is 
common (Turner-Warwick et al., 1991; Devita et al, 1997, Chiti et al, 1999).
Adenocarcinoma
This form of lung cancer is the second most common cause of NSCLC, and appears 
to be slightly more common in women than in men (Devita et al, 1997). However, 
in recent years the histological patterns of lung cancer have changed, with a world­
wide increase in adenocarcinoma, and a decrease in the proportion of squamous cell 
lung cancer (Payne, 2001). Indeed, in the United States, adenocarcinoma has 
become the most frequent subtype of NSCLC (Kreuzer et al, 1999). In Europe 
however, adenocarcinoma still remains the second most common cause of NSCLC 
despite substantial increase in incidence over the past twenty years (Harkness et al, 
2002). This increased incidence of adenocarcinomas is thought, in part, to be related 
to the decrease in the number of men smoking. Interestingly, it has also been
thsuggested that the introduction of the low tar cigarettes towards the end of the 20 
century may also be responsible for the increase in the number of adenocarcinomas 
being diagnosed (Levi et al, 1997; Payne, 2001). This is thought to be the case as 
the smoker, in order to satisfy the craving for nicotine, tends to compensate by
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increasing the number and depths of puffs. The bronchioloaveolar regions and the 
smaller bronchi, which lack protective epithelium, and where adenocarcinomas 
generally occur, are therefore exposed to higher concentrations of carcinogens (Levi 
etal., 1997).
These tumours are usually peripheral in origin and are found in the terminal 
bronchioles. They arise from glandular cells, such as mucous goblet cells, clara cells 
and type II pneumocytes, and are composed of cuboidal or columnar cells forming 
papillary structures. It has been suggested that they develop from either epithelium, 
bronchial mucosal glands or areas of scar tissue from old infarcts. However, it is 
also possible that this scar tissue is a product of the tumour itself. (Devita et al,
1997)
Under microscopic examination these tumours may be subdivided into several 
types:- acinar; papillary and mucus secreting. As the disease progresses, the tumour 
spreads along the alveolar walls and frequently invades the pleura (see Figure 1.4).
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Figure 1.4 Adenocarcinoma of the lung
(www.nlm.nih.gov/medlineplus/encv/imagepages/18014.htm; 
www. wi 11 roberts. com/1 un gcancer)
These tumours are known to progress rapidly and spread from lobe to lobe, 
ultimately encompassing both lungs. Adenocarcinoma is known to have a worse 
prognosis than squamous cell carcinoma, and at the time of diagnosis, distant spread 
is frequent (Devita et al, 1997; Chiti et al, 1999).
Bronchiolo-alveolar carcinoma is a subtype of adenocarcinoma of the lung, 
(Higashiyama et al., 1999). It is a relatively uncommon primary malignant 
pulmonary neoplasm, accounting for 2 to 14% of all pulmonary malignancies (Liu et 
al, 2000). The World Health Organisation categorise bronchiolo-alveolar carcinoma 
as a subtype of adenocarcinoma, and the increasing incidence of this subtype is 
thought to be contributing to the higher incidence of adenocarcinoma which has been
32
observed in recent decades (Breathnach et al, 1999; Liu et al, 2000). The aetiology 
of this increase in the incidence of bronchiolo-alveolar carcinoma is unclear. It tends 
to occur most frequently in female patients who have never smoked (Breathnach et 
al, 1999). The current definition of bronchiolo-alveolar carcinoma is, “malignant 
neoplasms of the lung that have no evidence of extrathoracic primary 
adenocarcinoma, an absence of a central bronchogenic source, a peripheral 
parenchyma location, no distortion of the pulmonary interstitium, and neoplastic 
cells growing along the alveolar septa" (Liu et al, 2000).
The histological criteria for bronchiolo-alveolar carcinoma includes a peripheral 
tumour manifesting the growth of well-differentiated cuboidal or columnar tumour 
cells along intact alveolar walls with no evidence of a primary adenocarcinoma at 
some extrapulmonary site. The cytologic criteria for a diagnosis of bronchiolo- 
alveolar carcinoma includes the prominence of monolayered tumour sheets, fine 
chromatin pattern, abundant cytoplasm showing uniformity, a high nuclear- 
cytoplasmic ratio, and mild cellular pleomorphism. Nuclear folds are a common 
finding, and cells nearly always lack cilia (Breathnach et al, 1999). Indeed, 
bronchiolo-alveolar carcinoma in lung adenocarcinoma, in which the tumour cells 
grow upon the pre-existing alveoli walls without damaging the underlying lung 
structure is often observed (Higashiyama et al, 1999). This type of tumour has been 
found to have a better prognosis than other types of non-small cell lung cancer.
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Large Cell Carcinoma
Large cell lung carcinoma is the least common type of non-small cell lung cancer, 
and represents only 10 to 20% of all non-small cell lung cancers that originate in the 
bronchi. Like squamous cell lung cancer, large cell lung cancer has a strong 
association with smoking. Although, the origin of the cells has not been established, 
it sometimes arises in the distal bronchus (see Figure 1.5).
Trachea
Large cell 
carcinoma
Bronchi * / \D A M
Figure 1 .5- Large cell carcinoma of the lung
(www.nlm.nih. go v/medlineplus/encv/imagepages/18015.htm; 
www.willroberts.com/lungcancer)
The cells are multinucleated and lack density; they also have moderate amounts of 
cytoplasm that lack evidence of mucus storage or keratinization (Turner-Warwick et 
al; 1991). This form of lung cancer may also exhibit giant cell forms, and 
occasionally the cytoplasm is pale staining. Hence, this tumour can be subdivided
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into two groups, giant cell and clear cell. Giant cell tumours represent a poorly 
differentiated subgroup and appear to have a poor prognosis.
At the time of diagnosis these tumours are usually large, and they are often 
accompanied by extensive tissue damage and distant spread (Devita et al, 1997). Of 
the three types of non-small cell lung cancer, large cell carcinoma has the worst 
prognosis. Similar to adenocarcinoma, the overall prognosis of those patients with 
advanced large cell lung cancer is poor with approximately 8% surviving five years 
(Devita et al., 1997; Chiti et al., 1999).
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1.4 Clinical assessment of lung cancer
1.4.1 Signs and symptoms of lung cancer
The majority of patients (90%) are symptomatic at the time of their diagnosis 
(Beckles et al., 2003). Cough and breathlessness are two of the most commonly 
occurring symptoms. For example Muers and Round (1993), in a study of 289 
patients with non-small cell lung cancer, found cough and breathlessness to be the 
most common symptoms experienced by the patient. Three-quarters of the patients 
included in the study were reported to have been experiencing cough and 
breathlessness, and this was found to be moderate or severe in approximately half of 
these patients. This has also been reported by Kuo and co-workers (2000), who in 
their study of old and young patients with non-small cell lung cancer, also found 
cough to be the most commonly presenting symptom, followed by breathlessness 
and chest pain. However, since these symptoms commonly occur in smokers, they 
are often not recognised until the disease in advanced.
It is also common for patients diagnosed with lung cancer to report haemoptysis at 
the time of diagnosis. However, this is rarely severe and usually consists of blood 
streaked sputum (Beckles et al, 2003). Chest pain is another common presenting 
symptom in patients with lung cancer, with more than 50% of patients reporting 
chest wall pain during the course of their disease. The pain tends to be unrelated to 
breathing or coughing being instead persistent and poorly localised. If however, a 
patient presents with chest wall pain which is particularly severe and localised, it is 
usually related to either direct invasion of the pleura or chest wall by the primary
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tumour, a rib metastasis or associated pneumonia or pulmonary infections (Beckles 
et al., 2003). Muers and Round (1993) reported that haemoptysis and chest pain 
occurred in approximately one third of the patients included in their study.
Other clinical features may include: anorexia, unexplained weight loss and / or loss 
of appetite, fatigue, pyrexia of unknown origin, bone pain or pathological fracture or 
hoarseness due to left recurrent laryngeal nerve palsy. Dysphagia may also develop 
if enlarged mediastinal nodes exert pressure on the oesophagus (Hancock and 
Bradshaw, 1981). Superior vena cava obstruction (SVCO) is also a frequent 
presentation of lung cancer, its clinical presentation includes oedema and vein 
distension of the head and neck and upper extremities and thorax, dyspnoea and in 
severe cases, confusion, impaired attention and coma (Urruticoechea et al, 2004). 
Many of these symptoms may be palliated by treatments such as radiotherapy 
(Muers and Round 1993).
For the majority of patients, irrespective of the type of lung cancer, treatments are 
based on the clinical stage of disease and the symptoms experienced by the patient 
(Muers and Round 1993).
Despite the continual high incidence of lung cancer within the Western world, five 
year survival remains low at 7 to 13%. This occurs as a result of approximately 80% 
of patients presenting with advanced inoperable disease. It is recognised that 
improvements in survival are only possible through patients being diagnosed sooner 
with resectable disease, which could perhaps increase five year survival to 70% 
(Porter and Spiro, 2000).
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1.4.2 Diagnosis and staging of small cell lung cancer
Over the past decade the proportion of patients with small cell lung cancer has 
decreased from 17.4% to 13.8%. Small cell lung cancer, like squamous cell lung 
cancer has a strong association with cigarette smoking; however the clinical nature 
of small cell lung cancer tends to be more aggressive. Without treatment, median 
survival is usually 2 to 4 months. (Brewis, 1991, Devita et al., 1997; Johnson, 1999; 
Simmonds, 1999; Simon et al., 2003). Accurate assessment of these patients is 
therefore essential to allow for the most effective treatment to be planned.
Small cell lung cancer is staged using a simple two stage system: limited or 
extensive stage, as described by the Veterans Administration Lung Cancer Study 
Group in 1965 (Naruke et al, 1997; Devita et al, 1997). Patients with limited 
disease are described as having involvement which is restricted to one hemithorax, 
although some definitions allow the ipsilateral supraclavicular nodes to be affected. 
Patients who are found to have metastatic disease in other parts of the body are 
defined as having extensive disease (Souhami, 1992; Simon et al, 2003).
Vincent and co-workers (1987) have questioned the value of this method of staging 
(due to the elaborate investigations involved), and suggested that a simpler clinically 
based system of staging may be more appropriate. This would include the use of 
clinical performance status and few simple biochemistry tests, which may provide 
better prognostic sub-groupings than that of conventional staging by extent of 
disease (Souhami et al, 1985; Osterlind and Anderson, 1986). Presently, the 
traditional methods of staging small cell lung cancer according to evidence of
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disease extent remains widely used (Yip and Harper, 2000), although many 
clinicians also used clinical and biochemical parameters as further guides to 
prognosis. For example, Souhami (1992) reported that in terms of survival, 
biochemical abnormalities such as a raised alkaline phosphate or lactic 
dehydrogenase or a low serum albumin or sodium concentrations are adverse 
prognostic factors.
In patients who are newly diagnosed with small cell lung cancer, a full medical 
history and physical examination should be performed. As part of this assessment, it 
is important to consider the patient’s performance status, since this will reflect the 
patient’s ability to tolerate treatment (Souhami, 1992; Simon et al, 2003). 
Histopathology specimens obtained at the time of diagnosis (by either bronchoscopy 
or biopsy) should be examined to determine the cell type (Simon et al, 2003). A CT 
scan of the chest and upper abdomen should be performed to assess the extent of the 
tumour; the whole liver and both adrenal glands being examined at this stage to 
determine any metastatic involvement. If neurological history or examination prove 
to be abnormal, a CT scan of brain maybe performed (Yip and Harper, 2000; Simon 
et al, 2003). Baseline blood parameters of full blood count, urea and electrolyte 
levels, liver function tests and lactic dehydrogenase levels are also usually performed 
(Simon et al, 2003).
Two thirds of those patients with SCLC present with extensive disease, and the 
remainder, 30 to 40% of patients, will be deemed as having limited disease, with no 
sign of the cancer beyond one side of the chest (Devita et al, 1997; Simmonds 
1999).
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It has been argued that TNM staging (see Figure 1.6) should also be applied in small 
cell lung cancer, as this provides significant information on prognosis and tumour 
spread (Souhami, 1992; Devita et al, 1997). Limited disease would correspond to 
stages I to IIIA, whilst extensive disease would correspond to stages Illb to IV 
(Naruke et al, 1997). However, as CT detection of early spread is limited, this is not 
widely practised.
1.4.3 Diagnosis and staging of non-small cell lung cancer
It is well recognised that in patients, with NSCLC, those who present with early 
stage disease (stage I and II) have the best possibility of cure, with a five year 
survival rate of 50 to 80% (Hespanhol et al, 1995; Juretic et al, 1999; Ferrigno and 
Buccheri, 2000). This however, represents less than 25% of this patient group 
(Nesbitt et al, 1995).
The majority of patients with NSCLC present with advanced disease, and this is 
associated with poor prognosis (Martins et al, 1999). The median survival in 
patients with NSCLC varies depending on the stage of their disease. Within Europe, 
across all stages of NSCLC, five year survival is reported to be less than 10% (Sant 
et al, 2001). However, in advanced stage IV disease less than 1% survive 5 years 
(Hespanhol et al, 1995; Ferrigno and Buccheri, 2000). The aim of staging in lung 
cancer is therefore to identify suitable patients for surgical resection and also those 
who many benefit from aggressive treatment (eg. Radical radiotherapy) of their 
locally advanced disease ( Leong et al, 1999; Hoffman et al, 2000).
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The staging assessment for NSCLC includes three main issues: the extent of spread 
within the chest; the presence of distant metastasis and the general health and 
physical function of the patient.
The chest is generally assessed by chest X-ray, bronchoscopy, pulmonary function 
testing and computerised tomography (CT scan). A chest X-ray may assist in the 
diagnosis of primary lung cancer, for example, by allowing for the identification of a 
spiculated, irregular pulmonary nodule or a lung mass with cavitation. Mediastinal 
adenopathy, pleural space abnormalities (e.g. mass, effusion) or skeletal 
abnormalities may also be identified (Grondin and Liptay, 2002).
Bronchoscopy is commonly performed to assess the extent of proximal bronchial 
disease, to exclude any additional lesions and to take biopsies for histology (30% of 
central tumours are diagnosed via bronchoscopy). Bronchial brushings and lavage 
may also be undertaken and a transbronchial biopsy of the peripheral lung may also 
be performed under radiological screening to obtain a tissue diagnosis (Hoffman et 
al, 2000; Grondin and Liptay, 2002).
A CT scan of the chest is carried out to assess any invasion by the tumour of the 
adjacent structures, and to look for hilar and mediastinal adenopathy. Although CT 
scanning has an accuracy of 88% in detecting mediastinal involvement, the presence 
of enlarged mediastinal lymph nodes on CT scan does not necessarily exclude the 
patient from surgery, as this may be a false positive result (due to post-obstructive 
infection of the resultant inflammatory lymphadenopathy). In such instances 
positron-emission tomography (PET) may be used, since this is a highly sensitive
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and specific scan for mediastinal staging. If mediastinal spread is suspected, then a 
mediastinoscopy may be performed to assess the involvement of the ipsilateral and 
contralateral mediastinal lymph nodes (Hoffman et al, 2000; Grondin and Liptay, 
2002). Magnetic Resonance Imaging (MRI) may also be useful in evaluating any 
intrathoracic spread. Other newer staging techniques include isotope labelled 
neospect scanning, video assisted thoracoscopy and transbronchial needle biopsy of 
mediastinal nodes (Deslauriers and Gregoire, 2000; Hoffman et al, 2000).
As previously acknowledged, metastatic involvement in patients with NSCLC is 
common. Grondin and Liptay (2002) reported that approximately 30% of patients 
have metastatic disease at the time of diagnosis. Common sites for metastatic spread 
include brain, bone, liver and adrenal glands (Deslauriers and Gregoire, 2000). In 
the assessment of metastatic spread the medical history and physical examination of 
the patient is useful. Full blood count, urea and electrolyte levels and liver function 
tests are also helpful. Elevated liver function tests are suggestive of liver metastases, 
while elevation in alkaline phosphate or calcium is suggestive of bone metastases 
((Grondin and Liptay, 2002). Metastases to the liver and adrenal glands are 
<commonly diagnosed by means of an abdominal CT scan; in some patients these 
lesions are too small to accurately characterise with CT scanning, and in such 
instances ultrasound clarification may be of added benefit. For those patients 
suspected of having bony metastases isotope bone scanning may be employed to 
(confirm these (Deslauriers and Gregoire, 2000). If brain metastases are suspected 
tthese may be diagnosed by a CT scan of the brain. However in those patients with a 
negative CT scan who have symptoms suspicious of brain metastases, MRI scanning 
may be useful.
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Assessment of the health and physical function of the patient usually involves a 
combined judgement about the patients performance status and their ability to 
tolerate certain treatments (Hoffman et al, 2000; Grondin and Liptay, 2002). In 
particular, assessment of cardio-respiratory fitness is important.
Staging of NSCLC is based on the TNM classification which was first proposed by 
Pierre Denoxi in 1946 as an anatomical basis for unifying staging (Naruke et al, 
1997; Beadsmoore and Screaton, 2003). Since its development the TNM 
classification has been modified several times, most recently in 1997 by Mountain. 
Despite these modifications, the original concept upon which staging was based 
remains (Beadsmoore and Screaton, 2003).
The T component of the classification provides information on the size and local 
extent of the primary tumour (Deslauries and Gregoire, 2000; Beadsmoore and 
Screaton, 2003).
The N component of the classification indicates the presence or absence of lymph 
node involvement (Deslauries and Gregoire, 2000; Beadsmoore and Screaton, 2003).
The M component of the classification provides information about the presence or 
absence of distant metastase (Deslauries and Gregoire, 2000; Beadsmoore and 
Screaton, 2003). See Figure 1.6
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Classifications Descriptions
Primary tumour(T)
Tx =
Primary tumour cannot be assessed, or tumour proven by the 
presence of malignant cells in sputum or bronchial washings 
but not visualised by imaging or bronchoscopy
TO = No evidence of primary tumour
T is =
Carcinoma in situ
T1 = Tumours <3cm in diameter, surrounded by lung or visceral 
pleura, without bronchoscopic evidence of invasion more 
proximal than the lobular bronchus (ie. Not in the main 
bronchus)
T2 = Tumour with any of the following features-
• > 3 cm in greatest dimension
• Involves the main bronchus, >2cm distal to the carina
• Invades the visceral pleura
• Associated with atelectasis or obstructive pneumonitis 
that extends to the hilar region but does not involve the 
entire lung
T3 = Tumour of any size that directly invades any of the following: 
chest wall (including superior sulcus tumours), diaphragm, 
mediastinal pleura, parietal pericardium; or tumour in the 
main bronchus < 2cm distal to the carina, but without 
involvement of the carina; or associated atelectasis or 
obstructive pneumonitis of the entire lung
T4 = Tumour of any size that directly invades any of the following: 
mediastinum, heart, great vessels, trachea, oesophagus, 
vertebral body, carina; or tumour with a malignant pleural or 
pericardial effusion, or with satellite tumour nodule(s) within 
the ipsilateral primary-tumour lobe of the lung
Regional lymph nodes(N)
NX = Regional lymph nodes cannot be assessed
NO = No regional lymph node metastasis
N1 = Metastasis to ipsilateral peribronchial and/ or ipsilateral hilar 
lymph nodes, and intrapulmonary nodes involved by direct 
extension of the primary tumour
N2 = Metastasis to ipsilateral mediastinal and/ or subcarinal lymph 
node(s)
N3 = Metastasis to contralateral mediastinal, contralateral hilar or 
ipsilateral or contralateral scalene or supraclavicular lymph 
node(s)
Distal metastasis(M)
MX = Presence of distant metastasis cannot be assessed
MO = No distant metastasis
[ m ^ ~ Distant metastasis present
Figure 1.6 TNM Description
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NSCLC may be allocated into four categories in accordance with TNM staging. (See 
Figure 1 7).
STAGE Description 5-year survival rate (%)
IA T l, NO, MO -  Peripheral “coin” lesion 6 0 - 8 0
IB T2, NO, MO -  Involving the mainstem bronchus > 2cm distal
to carina; Involving visceral pleura
Small tumour, no evidence of lymph node or other distant
metastasis
IIA
IBB
T l, N l, MO - < 3cm involving peribronchial lymph nodes 
(by direct extension)
T2, N l, MO -  Involving visceral pleura and peribronchial 
and hilar lymph nodes
T3, NO, MO -  Involving main bronchus < 2cm distal to 
carina
2 5 - 5 0
III A Tl -  T3, NO -N 2 , MO
Various size tumours involving ipsilateral hilar and 
mediastinal lymph nodes
2 5 - 4 0
III B Any T4 or anyN3, MO
Primary tumour invasion of the mediastinum and metastasis 
to contralateral hilar, contralateral mediastinal or scalene / 
supraclavicular lymph nodes
<5
IV Any T, any N, Ml 
Distant metastasis
<5
Figure 1.7 - Staging using TNM classification (Deslauries and Gregoire 2000; 
Mountain, 1997, Devita et al.} 1997, Naruke et al., 1997)
However, Leong and co-workers (1999) suggested that as patients with pleural 
effusions have a poor survival, similar to that o f patients with stage IV disease (ie. 
spread to the brain or liver), they should be reclassified as having stage IV disease.
Accurate assessment o f lung tumours is necessary to allow for appropriate treatment 
to be planned (Leong et al., 1999).
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1.55 Treatment Options
Thie treatment for lung cancer may differ depending on whether the cancer is 
claassified as small cell lung cancer or non-small cell lung cancer (Simmonds, 1999).
1.55.1 Small cell lung cancer
Srmall cell lung cancer (SCLC) comprises approximately 20 to 25% of all lung 
camcers. Due to the systemic nature of small cell lung cancer, it is almost invariably 
dissseminated or at least so locally advanced at the time of diagnosis that surgery is 
rarcely a feasible option (Kumar, 1997; Spiro and Porter, 2002). If untreated, patients 
witth limited SCLC have a median survival of three months, compared with only six 
weeeks in those patients with extensive disease (Kelly, 2000; Spiro and Porter, 2002).
In 1 the 1970’s it was recognised that SCLC was extremely sensitive to cytotoxic 
chemxotherapy; indeed, there was a time in the 1980’s when SCLC was considered to 
be ] potentially curable. This resulted in numerous clinical trials to investigate the 
effiicacy of different chemotherapy combinations, alternating chemotherapy and the 
durration of chemotherapy (Splinter, 1997; Spiro and Porter, 2002).
Siimmonds (1999) suggested that chemotherapy should commence within two weeks 
of a confirmed histological diagnosis, as this can provide rapid palliation of 
syimptoms and may improve survival time. The treatment given to patients with 
SCILC will largely depend on extent of disease, performance status, and biochemical 
resiults eg. alkaline phosphate, lactate dehydrogenase (Souhami, 1992). For those
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patients with limited disease, accounting for approximately one third of all SCLC 
cases, chemoradiation therapy may be employed (Kumar, 1997; Johnson, 1999; 
Spiro and Porter, 2002; Simon and Wagner, 2003). Combined chemotherapy in 
most instances is usually administered for six courses, as fewer treatments have been 
associated with a reduction in the disease free interval after chemotherapy (Spiro and 
Poter, 2002). It is well recognised that despite the high response rates to 
chemotherapy in patients with SCLC, relapse and progression commonly occurs 
(Kumar, 1997; Johnson, 1999; Kelly, 2000).
Kumar (1997) reported that although chest irradiation has been used in the treatment 
of SCLC over the past four decades, its standard role in the treatment of limited stage 
disease has only been established over the past decade. It has also been reported that 
the addition of thoracic radiotherapy to chemotherapy usually results in a halving of 
local failure rates from more than 60% with chemotherapy alone to approximately 
30% with combined chemotherapy and radiotherapy. An improvement in three year 
survival from 10 to 15% following chemoradiation was also reported (Kumar, 1997).
Due to the systemic nature of SCLC, the current treatment for limited disease 
integrates chemotherapy for the management of undetected micrometastases which 
are usually present at diagnosis, with thoracic radiotherapy to improve locoregional 
tumour control (Kumar, 1997).
It has recently been reported that of those patients treated with chemoradiation 
therapy for limited SCLC, approximately 20% of patients will achieve complete 
remission of the disease (Simon and Wagner, 2003). However, despite this, several
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issues remain problematic in the administration of chemoradiation therapy in 
treatment of limited SCLC. These include timing and concurrent vs sequential vs 
alternating treatment (Kumar, 1997; Johnson, 1999). It has been suggested that the 
best survival results are achieved when using early concurrent thoracic radiotherapy 
with cisplatin based chemotherapy as opposed to sequential or alternating regimes 
(Kumar, 1997; Johnson, 1999). This improvement in survival may be associated 
with an increase in toxicity. However, for the combination of cisplatin and 
etoposide, a commonly used regime, long term toxicity appears to be modest, with 
short term toxicities consisting primarily of oesophagitis which is manageable 
(Johnson, 1999).
Spiro and Porter (2002) reported in their review of those patients treated with either 
chemotherapy alone or chemoradiation therapy, who achieved a complete response 
to their treatment, that the cumulative risk of developing a brain metastasis was 50%. 
This is often the first site of relapse, with survival after such relapses being short and 
morbidity high. Prophylactic cranial irradiation (PCI) has been reported to reduce 
the incidence of cerebral metastasis when administered to those patients who have 
achieved a complete response after treatment. Clear evidence exists from meta­
analysis that PCI improves overall and disease-free survival rates for patients with 
SCLC in complete remission._(Johnson, 1999; Spiro and Porter, 2002; Pottgen et al, 
2004).
The prognosis for those patients diagnosed with extensive disease is extremely poor. 
Four to six courses of platinum based chemotherapy tends to be the first line 
treatment of choice for patients with extensive disease (Hanna and Einhom, 2002;
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Spiro and Porter, 2002). However, a balance must be obtained between the toxicities 
exerted by the chemotherapy agents, and patient quality of life and survival. Patients 
are unlikely to live for many months even with chemotherapy, and “aggressive” 
management must be reviewed in this light. In order to reduce toxicity, the number 
of courses or the strength of each dose of chemotherapy may be required to be 
reduced (Simmonds 1999; Spiro and Porter, 2002). Overall response rates from 
treatment range from 60 to 80% with a median survival of less than 14 months; less 
than 30% of patients remain disease free for two years (Devita et al, 1997, Johnson,
1999).
1.5.2 Non-small cell lung cancer
It has long been recognised that the treatment of non-small cell lung cancer is one of 
the most frustrating areas in oncology (Mulshine et al, 1986).
Since the first surgical resection for a primary lung cancer was performed in 1933 by 
Graham and Singer, surgical treatment for patients with stage I and II, and some 
patients with IIIA disease remains the ‘gold standard’ (Delauries and Gregoire, 2000; 
Orlowski and Szczensy, 2001). Unfortunately, despite surgery being the only 
treatment to offer the best chance of long term survival and cure, the majority of 
patients present with inoperable disease as the tumour is either locally advanced or 
has metastasised elsewhere within the body (Juretic et al, 1999; Simmonds, 1999; 
Bunn et al, 2000; Gridelli et al, 2003). Indeed, fewer than 25% of patients will 
present with stage I or stage II disease, with the average five year survival reported at 
approximately 65% and 40% respectively (Nesbit et al, 1995). Even with complete
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resection at least half the patients will relapse with locally advanced and or 
metastatic disease within five years, resulting in a five year survival of between 20 to 
60% (Simmonds 1999; Deslauries and Gregoire, 2000; Ferrigno and Buccheri, 2000; 
Griddelli et al, 2003; Maas et al, 2003; Westeel and Depierre, 2003).
Approximately, 30% of patients present with stage Ilia or Illb disease, which is 
classed as loco-regional disease as it is confined to the chest wall without any 
obvious distant metastases. The potential role for surgery between these stages of 
disease is different, with stage Ilia being classed as potentially resectable; despite it 
carrying a high rate of recurrence and a post-operative 5 year survival of only 10 to 
30%. In general, stage Illb disease is considered to be unresectable (Ferrigno and 
Buccheri, 2000).
Full pre-operative staging work up is essential to select those patients who are most 
suitable for surgery. This includes, assessment of the patients performance status, 
physical function and cardio-respiratory function. The extent of disease should be 
assessed by staging procedures such as Chest X-ray; CT, MRI, PET scanning or 
mediastinoscopy, and reference to the TNM classification (Souhami, 1992; Bauman 
et al, 2001; Orolowski and Szcensy, 2001).
For those patients with stage I disease whose tumour is limited to a lobe, lobectomy 
is the most common operative procedure. When the tumour crosses the fissure and 
extends into the main bronchus (stage II disease), pneumonectomy is more 
commonly performed. In some patients with early stage disease, pulmonary reserve 
is poor and this results in wedge resection with chest wall resection. Occasionally, in
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patients with peripheral T3 tumours, where the malignancy invades the chest wall, 
lobectomy with chest wall resection may still be considered suitable surgery. 
However, this type of surgery carries a three fold increased risk of local recurrence. 
In view of this increased risk of local recurrence, post-operative radiotherapy is 
routinely recommended (Deslauries and Gregoire, 2000; Bauman et al, 2001).
Nevertheless, a proportion of patients technically suitable for surgery, do not 
undergo surgery for a variety of reasons. The majority of patients with lung cancer 
are middle aged or elderly, and are inoperable as a result of pre-existing comorbidity, 
mostly cardiopulmonary, that prohibits surgery due to a predicted high peri-operative 
risk. A small group of patients will refuse surgery. Those patients deemed 
unsuitable for surgery are usually offered radical radiotherapy either alone or in 
combination with chemotherapy. This is considered the ‘standard’ treatment 
approach and is thought to offer the only chance of cure in localised NSCLC 
(Hoffman et al, 2000; Baumann et al, 2001; Jeremic et al, 2002).
Radical radiotherapy is usually given to patients with stage Ilia and Illb disease in an 
attempt to improve survival and reduce the incidence of local recurrence (Spiro and 
Porter, 2002). This consists of 1.8 to 2.0Gy per fraction and five fractions per week 
to total doses of 60Gy (Juretic et al, 1999; Baumann et al, 2001; Jeremic et al, 
2002). Hoffman and co-workers (2000) reported cure rates of 25% in patients with 
early stage NSCLC who are treated with radical radiotherapy. Local tumour control 
with this form of treatment is only 10 to 20%, with local failure being reported as the 
leading cause of death after radiotherapy (Baumann et al, 2001). Indeed median
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survival of patients treated with radiotherapy alone is 10 months or less, with a five 
year survival of 5 to 10% (Numico et al, 2001).
The introduction of the highly accelerated radiotherapy CHART regime (continuous 
hyperfractionated accelerated radiotherapy), where treatment is administered three 
times daily as 1.5Gy for a total of 54Gy, has been reported to improve two year 
survival by 9% compared with standard radiotherapy (Baumann et al, 2001; Spiro 
and Porter, 2002). Baumann and co-workers (2001) reported that, radiotherapy may 
be combined with chemotherapy (mainly platinum based), given either sequentially 
or concurrently. This is now established as a standard treatment for patients with 
stage III NSCLC, with a 4% survival benefit observed at two years. It is however, 
important to remember that with advances in treatment, the toxicity experienced by 
the patient may also increase. Therefore patients need to be carefully selected for 
treatment (i.e. those patients with good performance status) and maximum tolerated 
doses need to be defined for each of these treatment approaches, in order to obtain 
maximum benefit (Baumann et al, 2001).
At the time of diagnosis, approximately 50% of patients have advanced (stage IV) 
disease (Nesbitt et a l ., 1995; Chiiti et al, 1999). Prognosis in this cohort of patients 
is extremely poor, with 80% of patients dying within one year of diagnosis 
(Hespanhol et al, 1995; Espinosa et al, 1995 Naruke et al, 1997; Numico et al, 
2001). The advanced nature and high metastatic potential of NSCLC results in 
widespread organ involvement which may cause a variety of symptoms including 
breathlessness, cough, anorexia, and weight loss. These tumour related symptoms 
commonly affect the patient’s quality of life. The aim of treatment is therefore
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directed towards the palliation of these symptoms, in an attempt to improved quality 
of life (Numico et al., 2001). Radiotherapy, chemotherapy, chemoradiation or 
supportive care is commonly offered to patients, and may have a role in the 
palliation of symptoms, improvement in quality of life and perhaps prolongation of 
survival.
On the basis of various meta-analysis, chemotherapy whenever practicable is 
recognised as a useful treatment for patients with stage IV disease, as it has been 
found to confer a small but statistically significant survival advantage (Ferrigno and 
Buccheri, 2000). Cisplatin has been incorporated into almost all chemotherapy 
regimes, since it has been shown to lengthen survival (Splinter, 1997; Bunn et al.,
2000). Prior to 1990, single agent chemotherapy such as Cisplatin was shown to 
produce response rates of 30%, with one year survival rates of 10 to 12%. Since the 
1990’s several new agents have been introduced. These include the taxanes 
(paclitaxel and docetaxel), gemcitabine and vinorelbine; when these agents are 
combined with cisplatin overall response rates of 30 to 40% have been reported, with 
median survival of 8 to 10 months and one year survival of 35% (Hespanhol et al., 
1995; Ferrigno and Buccheri, 2000).
Most oncologists tend to agree that due to the poor outlook for patients with 
inoperable NSCLC, platinum based chemotherapy should only be offered to those 
patients with a good performance status (i.e. ECOG-ps 0-1), as those with a poor 
performance status (i.e. ECOG-ps 2-4) have been shown to have a poor response to 
such treatment (Espinosa et al., 1995; Manegold, 2001). Those patients with ECOG- 
ps 2, will be considered by many oncologists to be of ‘good or bad’ performance
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status and in such instances may consider the patient for single agent chemotherapy 
(eg. gemcitabine) since platinum based combinations have been shown to have no 
survival benefit (Manegold, 2001). This method of selection may be seen to be 
rather inconsistent and possibly the use of various haematological and biochemical 
factors (e.g. haemoglobin, white cell count, lymphocyte count, albumin 
concentration and C-reactive protein), which are recognised prognostic factors, may 
be of assistance (Sorensen et al, 1989; Paesmans et al, 1997; Herndon et al, 1999). 
Thus, helping to better identify those patients suitable for oncological intervention.
For those patients who are ineligible for chemotherapy (eg. ECOG PS < 2) or when 
local symptoms are prevalent, palliative radiotherapy may help to relieve local 
symptoms of lung cancer. Chest pain, cough and breathlessness, may be relieved in 
some cases, with haemoptysis being controlled in 90% of cases. The median 
duration of such palliation is however often only 7 to 14 weeks (Numico et al, 2001; 
Spiro and Porter, 2002).
It is also well recognised that patients with lung cancer, especially when advanced, 
suffer from progressive weight loss and cachexia. This leads to muscle wasting, a 
reduction in performance status and ultimately death (Vansteenkiste et al, 1996; 
Brown and Radke, 1998). Various studies have demonstrated that those patients 
suffering from cancer cachexia have a poorer response to treatment and reduced 
survival (Heckmayr and Gatzemeier, 1992; Tisdale, 1998). Therefore it is important 
to consider the mechanisms underlying the progression of cachexia (Bruera, 1998) in 
the lung cancer patient.
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1.6 Weight loss and physical function in lung cancer
The majority of lung cancer patients with advanced disease suffer from significant 
weight loss, known as cancer cachexia. The term cachexia describes emaciate 
disease states and is based on the Greek word “kakos” meaning bad and “hexis ” 
meaning condition (Gough et al .,1996; Bruera and Portenoy, 1998). Cancer 
cachexia is a major cause of cancer associated death.
It has been reported that between 45 to 60% of patients with lung cancer experience 
weight loss at the time of diagnosis, increasing to almost 100% as the disease 
progresses (Brown and Radke, 1998; Bruera and Portenoy, 1998).
This progressive involuntary weight loss, in lung cancer patients, is associated with a 
decreased physical functioning, decreased psychological well being and poor quality 
of life. Irrespective of tumour type, patients with significant weight loss also have a 
poorer response to treatment (Chlebowski et al, 1996). Furthermore, survival may 
be decreased by 30 to 50% even in moderate weight loss (Chlebowski et al., 1996). 
Indeed a significant proportion of these patients will die as a result of severe wasting 
(Leij-Halfwerk et al, 2000). Attempts to reverse this wasting by the use of enteral 
or parenteral nutrition have failed to improve survival (Bruera and Portenoy, 1998).
The pattern of increased energy expenditure experienced by these patients in the face 
of anorexia and reduced calorie intake is one of the features that distinguishes the 
cachetic syndrome from starvation. In healthy individuals, when calorie intake is
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reduced, energy expenditure is diminished and body lipids are utilised, lean muscle 
being preserved (Bruera and Portenoy, 1998).
In the cachetic cancer patient it is the loss of adipose tissue that constitutes the 
majority of the weight loss. However, it is thought that it is the depletion of skeletal 
muscle which occurs later in this syndrome which is more significant in terms of the 
survival of these patients. This loss of skeletal muscle results directly from a 
depletion in the host protein (McMillan et al, 2001b). Therefore, any therapies 
directed at halting or reversing that cachexic syndrome should focus on the 
preservation of the host proteins, as loss of the protein stores may result in the death 
of these patients once the critical mass has been reduced (Bruera and Portenoy,
1998). The loss of skeletal muscle mass experienced by these patients has also been 
identified as a causative factor in the reduced performance status seen in these 
patients (McMillan et al, 2001b).
Several authors have examined the effects of drug therapy on the cachexia associated 
with lung cancer. A number of studies have suggested a role for megestrol acetate or 
similar progestagens (eg. medroxyprogesterone acetate) to improve appetite and 
promote non-fluid weight gain in lung cancer patients (Vansteenkiste et al, 1996; 
Chlebowski et al, 1996; Bruera and Portenoy 1998). Corticosteroids have also been 
used to improve performance status and weight gain. However, this improvement is 
short lived and the prolonged use of corticosteroids in this situation may lead to 
significant muscle myopathy (Hardy et al, 2001).
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In lung cancer it is thought that the cachectic state occurs due to both insufficient 
energy intake and hypermetabolism. The resultant negative energy balance leads to 
a loss of adipose tissue and protein mass (Mullen 1994; Jebb et al, 1994; Fredrix et 
al, 1997; Bruera and Portenoy, 1998) The resultant loss of this lean body mass, 
leads to reduced performance status, reduced quality of life, reduced survival and 
ultimately death (Vansteenkiste et al, 1996).
It has long been recognised that in patients with lung cancer, physical function as 
assessed by performance status is an important prognostic factor independent of the 
extent of disease, presence or absence of weight loss, bone pain and liver metastases 
(Capewell and Sudlow, 1990; Yip and Harper, 2000). Physical function tests (e.g. 
chair tests) may also be important in assessing hospital outcome (Covinsky et al, 
1997). However, such functional tests have not yet been used extensively to predict 
outcome.
Lung cancer has also been reported to have a greater impact on the physical function 
and ability of the patients to undertake their activities of daily living independently, 
than other types of cancer. For example, those patients with advanced staged lung 
cancer appear to experience more problems with physical functioning than patients 
with advanced stage colonic cancer, and they also experience more impairments of 
physical functioning and global quality of life than advanced prostate cancer patients 
(Ganz et al, 1991; Stafford and Cyr, 1997).
The occurrence of fatigue and functional decline has long been associated with 
chemotherapy and radiotherapy treatments (Smets et al, 1993). Sama (1994) also
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considered the functional status of women with lung cancer, and observed that 50% 
of the studied group had a serious reduction in energy levels and fatigue.
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1.7 The Inflammatory Response in Lung Cancer Patients
The inflammatory response that may occur in cancer patients has been likened to that 
of wound healing. Dvorak (1986), described a tumour as “a wound that does not 
heal”. This is because unlike simple wound healing, the tumour causes continuous 
activation of white blood cells, secretion of a vascular permeability factor, vascular 
endothelial growth factor. This can lead to increased fibroblast activity, resulting in 
continuous generation of the extracellular matrix.
In addition, it has been reported that pro-inflammatory cytokines and chemokines 
(eg. tumour necrosis factor (TNF), IL-1 and IL-6), which can be produced by the 
tumour cells may contribute directly to malignant progression (Balkwill and 
Mantovani, 2001).
TNF is a major mediator of inflammation, with actions contributing to both tissue 
destruction and recovery. Whilst dealing with the death of diseased cells at the site of 
inflammation, TNF stimulates fibroblast growth. As part of the local systemic 
response TNF selectively destroys the tumour blood vessels. However, in states of 
chronic inflammation (systemic inflammatory response) this cytokine may act as an 
endogenous tumour promoter, contributing to the tissue remodelling and stromal 
development necessary for tumour growth and spread.
Balkwill and Mantovani (2001), in their review, reported that inflammatory 
cytokines and chemokines have the potential to prevent cell apoptosis, and some of 
them may also act as growth and survival factors for malignant cells. IL-6 is a
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growth factor, whilst IL-1 has growth stimulating activities. In many tumours, 
including lung cancer, pro-inflammatory and inflammatory cytokines and 
chemokines are involved in the regulation of tumour growth.
This systemic reaction can also be characterised by alterations in protein metabolism 
resulting in the loss of lean tissue. It has been suggested that the metabolic changes 
underlying cancer cachexia may be due to pro-inflammatory cytokines, for example 
tumour necrosis factor (Tracey et al, 1988), interleukin lp (Dinarello, 1988) and 
interleukin 6 (Fearon et al, 1991). The production of acute phase proteins, such as 
C-reactive protein (CRP) and lipopolysaccharide-binding protein (LBP), is also 
associated with the inflammatory response. Of these, the serum C-reactive protein 
concentration is the most commonly used inflammatory marker (Heinrich et al, 
1990).
Interleukin 6 (IL-6) has been identified as one of the principle regulators of the acute 
phase response (Heinrich et al, 1990). Work has shown that an increase in the 
circulating concentrations of IL-6 and C-reactive protein is correlated and associated 
with weight loss in lung cancer patients (Scott et al,. 1996). Furthermore, there is 
some evidence that these pro-inflammatory cytokines, may also be produced by the 
lung tumour cells themselves (Martin et al,. 1999).
At the time of diagnosis most patients with non-small cell lung cancer have been 
shown to have evidence of an inflammatory response. This is commonly identified 
by increased circulating concentrations of C-reactive protein levels or interleukin 6 
(Scott et al,. 1996). Scott and co-workers (1996) also reported that the presence of
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the acute phase response may be identified by the presence of a raised white cell 
count and neutrophil count. Martins and co-workers (1999) reported that 
concentrations of cytokines (e.g. IL-1, IL-6) and acute phase proteins (e.g. C-reactive 
protein) were similar in patients with either small cell or non-small cell lung cancer.
As previously discussed these pro-inflammatory cytokines and acute phase proteins 
have been reported to be associated with the increased resting energy expenditure 
and an increase loss of lean tissue (see Section 1.6).
Therefore, it may be, as suggested by Scott and co-workers (1996), that the use of 
anti-inflammatory agents would moderate the systemic inflammatory response, thus 
reducing resting energy expenditure and loss of lean tissue, hopefully improving 
performance status and ultimately the survival of patients with non-small cell lung 
cancer. However, before such studies are carried out it would be important to 
establish the relationship between the systemic inflammatory response, performance 
status and survival in patients with inoperable NSCLC.
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1.9 Aims of thesis
The prognosis of patients with inoperable non-small cell lung cancer remains bleak. 
Traditionally, various factors have been linked to the observed poor survival rate; 
these include stage of disease, performance status and weight loss. It has been 
proposed that the presence of the systemic inflammatory response is an important 
underlying factor contributing to the weight loss seen. Despite this, few studies have 
examined the value of the systemic inflammatory response as a prognostic factor in 
patients with inoperable non-small cell lung cancer.
The aims of this thesis are:
1. To examine the relationship between anthropometric parameters, the 
systemic inflammatory response and ECOG-performance status in patients 
with inoperable non-small cell lung cancer
2. To develop and evaluate an inflammation based prognostic score in patients 
with inoperable non-small cell lung cancer.
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2 METHODS: - ASSESSMENT OF BODY COMPOSITION
2.1 Introduction
As recognised in section 1.6, weight loss is a common presenting feature in patients 
with lung cancer. Approximately 60% of patients have experienced weight loss at 
the time of their diagnosis, with almost 100% experiencing weight loss as their 
disease progresses (Brown and Radke, 1998; Bruera and Portenoy, 1998). Since it is 
acknowledged that this weight loss is associated with decreased physical 
functioning, psychological well being, quality of life and ultimately decreased 
survival (Chlebowski et al, 1996; Simons et al, 1999; McMillan et al, 2001b), it is 
essential to attempt to understand these weight changes, in relation to the tissue 
alterations which occur within these patients. Several studies have reported that 
weight loss in patients with cancer cachexia reflects wasting of both fat mass and 
body cell mass. This is demonstrated mainly by loss of adipose tissue and skeletal 
muscle (Heymsfield and McManus, 1985; McMillan et al, 1994; Simons et al, 
1999; Leij-Halfwerk et al, 2000). Indeed, in lung cancer patients, this weight loss is 
recognised to be secondary to a systemic effect of the tumour. Weight loss has also 
been shown to be related to increased morbidity and to be of prognostic significance, 
both in terms of decreased response to treatment and reduced survival (Brown and 
Radke, 1998).
The human body can be considered to be composed of various components. Several 
models have been used to describe these. Commonly, body mass is described as 
being composed of two major elements; fat free mass and fat tissue which contain
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water and no water respectively. The fat free mass can further be subdivided into 
two compartments; body cell mass and extra-cellular mass. The body cell mass is 
composed of muscle mass (60%), viscera (20%), and other components including 
red cells, tendon, bone and cartilage (20%). The extra-cellular mass includes fluids 
and solids (Shizgal, 1985), (see Figure 2.1). Over five decades ago Pace and 
Rathbum (1945) reported that the fat-free mass consists of approximately 73% 
(range 70% -  76%) of water, and consequently if body weight and body water are 
known, this percentage can be used to estimate both fat mass and fat free mass.
In patients with advanced cancer, body composition is commonly assessed by 
measurements of height and weight. A patient’s body weight may be recorded at the 
initial presentation of their illness; this may be compared to their pre-illness weight, 
and the percentage of weight loss calculated. Weight can be combined with height 
to give the standardised measurement of Body Mass Index (BMI, normal range 20 -  
25).
Despite weight and BMI being simple and easy to perform, they are limited as 
measurements of nutritional status. A major limitation of such measurements is their 
inability to distinguish between body fat and lean tissue, since weight may be 
increased due to the presence of ascitic fluid or peripheral oedema (Talbot and 
Lister, 1995). Moreover, a large tumour or organomegaly can mean that a patient 
may have lost little weight, but has lost significant amounts of fat and skeletal 
muscle (Heymsfield and McManus, 1985; Heymsfield and Matthews, 1994; Burman 
and Chamberlain, 1996). For this reason other methods of assessing body
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composition are employed to evaluate the wasting experienced by these patients 
(Pichard and Kyle, 1998).
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2.2 Fat and fat free mass
The measurement of skinfold thickness and arm circumference is an effective and 
useful method of distinguishing the percentage of body fat compared with fat free 
mass (Talbot and Lister, 1995). It is well recognised that in healthy individuals the 
majority of fat is stored subcutaneously; as a result various skinfold thickness 
measurements have been developed to estimate the total body fat of an individual 
(Dumin and Womersley, 1974; Burman and Chamberlain, 1996). The skinfold 
calliper is the instrument used to measure subcutaneous fat. This is a portable, non- 
invasive and accurate method of assessing the patients skinfold thickness. 
Recognised areas for sampling include triceps, biceps, subscapular and suprailiac 
skinfolds. This method makes the assumption that subcutaneous fat is a reflection of 
total body fat and that the average thickness of fat is the same as at the selected 
skinfold sites (Jebb and Elia, 1993; Burman and Chamberlain, 1996). A series of 
regression equations have been developed which allow for the prediction of total 
body fat and fat free mass from a combination of sites (see Figure 2.2). Although 
these measurements are probably the most widely used technique for estimating fat 
mass, significant inter-observer variability is well recognised. It has been reported 
that there is a variation of 6 -  24% in skinfold thickness measurements (Burkinshaw 
et al., 1973; Harries et al, 1983). Despite these limitations, various studies have 
showed it to be a useful method of detecting differences between weight losing and 
non-weight losing cancer patients (Watson and Sammon, 1980; Bozzetti et al, 1982; 
Hansell et al, 1986, O’Gorman et al, 1998).
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Mid upper arm circumference is another well-recognised method of assessing muscle 
mass and lean tissue within the body (Harries et al., 1983; Burman and Chamberlain, 
1996). This is carried out using a non-stretchable tape measure, the measurement 
should be taken at the mid point between the lateral projection of the acromion 
process of the scapula and the inferior margin of the olecranon process of the ulna. 
Compared with skinfold anthropometric measurements, errors are approximately 10 
fold less using this method (Harries et al, 1985).
In order to calculate muscle circumference the limb circumference (C ]jmb) is 
corrected for subcutaneous adipose tissue, the skinfold calliper measurement (S) is 
assumed to be twice the subcutaneous adipose tissue thickness (Lee et al, 2000).
Mid upper arm circumference may therefore be useful a method of assessing the loss 
of lean tissue in the weight losing cancer patient, as it reflects muscle and fat, and is 
related to function. Indeed, in a recent study by McMillan and co-workers (2002) it 
was reported that mid upper arm circumference showed good correlation with 
performance status.
The ease of observer use and good patient compliance with anthropometric 
measurements means that these methods are suitable for the assessment of body 
composition in lung cancer patients, however this assessment is not frequently used 
in clinical practice.
In studies of weight losing cancer patients, fat free mass can also be derived from the 
measurement of total body water. Since total body water has been identified as the
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largest chemical component in mammals, in health it is closely associated with lean 
tissue (Wang et al, 1999). Total body water can be measured using the technique of 
bioeletrical resistance impedance (BIA), in which the property of electric ionic 
conduction of soft tissue is measured to estimate intracellular and extracellular water. 
The basic principle of this method of assessment is that lean tissue conducts, whereas 
fat acts as an insulator. However, it is now widely recognised that alterations in the 
degree of hydration of the fat free mass, usually resulting in an increase in 
extracellular fluid, may confound this estimation. For example, in a recent study, 
McMillan and co-workers (2000) showed that compared with the reference method 
of total body potassium, the measurement of total body water over-estimates the 
amount of metabolically active tissue by approximately 20%.
In summary, it is important that any weight changes resulting from treatment can be 
assessed by establishing in which type of tissue the alteration has occurred (adipose 
or lean tissue). In the present work, body composition was estimated using minimally 
invasive measurements of height, weight, skinfold thickness (triceps and biceps), and 
mid-upper arm circumference in patients with inoperable non-small cell lung cancer.
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2.3 Body Composition Measurements
2.3.1 Height, Weight and Body Mass Index
The height of individual patients was measured at each clinic visit. Asking patients 
to stand upright in stocking feet, a standiometer was used to measure their height to 
the nearest centimetre.
Their weight was measured using a set of Weylux scales (Made in England, Model 
424), with patients wearing indoor clothing and no shoes. Weighing took place on a 
flat non-carpeted floor. Weight was recorded (to the nearest 0.1kg) in the patient’s 
casesheet. The following equation was used to calculate body mass index:
Body Mass Index (KG/M2) = Weight (kg) * Height2 (m2)
2.3.2 Skinfold and Mid- upper arm circumference
Skinfold thickness was measured using Harpenden skinfold callipers (Holtain Ltd., 
Crymych, United Kingdom). A stretch resistant measuring tape was used to 
accurately measure limb circumference. The two sites identified for measuring 
skinfold thickness were biceps and triceps (see Figure 2.2). Once the measurement 
site was identified, the skinfold was grasped firmly between the thumb and the index 
finger. To ensure that fat and not muscle was measured the patient was asked to 
contract the muscle beneath the site of measurement. This ensured a true 
measurement of subcutaneous fat. The patient was then asked to relax their arm, 
and the callipers applied 1 cm below the observer’s fingers. When the two surfaces
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of the callipers are parallel, the pressure of the callipers and the calliper needle 
stabilises, then the measurement can be taken. In order to minimise error, 
measurements were made in triplicate and the average score recorded as 
recommended by other workers in this field (Womersley and Dumin, 1973; 
Burkinshaw et al, 1973; Jebb and Elia, 1993; Talbot and Lister, 1995; Burman and 
Chamberlain, 1996). To minimise inconvenience to this frail, sick group of patients 
subscapular and suprailiac measurements were not carried out.
The triceps skinfold thickness measurement was performed using the mid point of 
the triceps muscle between the acromion process of the scapula and the olecranon of 
the ulna of the arm. The biceps skinfold thickness was measured at the same level as 
the triceps, over the biceps muscle, midway between the auxiliary fold and the 
antecubital fossa. During both measurements the patients were standing with their 
arms extended and relaxed by their side (see Figure 2.3).
Mid-upper arm circumference was measured with reference to the acromion process 
and the olecranon, i.e., at the same point as the skinfold measurements. The tape 
was maintained in a horizontal position, touching the skin lightly, but not 
compressing the underlying skin (see Figure 2.3).
All measurements were repeated three times, and performed by the same investigator 
in an attempt to reduce the error margin.
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Figure 2.1 Simple models of body composition
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Figure 2.2 Anthropometric measurements- calculation of fat and fat-free mass
Since during the course of this study the two areas chosen to perform skinfold 
anthropometric measurements were triceps and biceps only these equations are listed 
below
1. Determine the patients height and weight (kg)
2. Add skinfold thickness for triceps and biceps (Z)
3. Compute the logarithm Z
4. Apply one of the following age /sex adjusted equations to calculate body 
density
Men
Age range
17-19 D = 1.1423-0.0687 x(logZ)
2 0 -29 D = 1.1307-0.0603 x(logZ)
30-39 D = 1.0995-0.0431 x(logZ)
4 0 -49 D = 1.1174-0.0614 x(logZ)
50+ D = 1.1185-0.0683 x(logZ)
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Figure 2.3 Photographs of skinfold anthropometry
Biceps Triceps
Mid-upper arm circumference
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3 METHODS:- PROGNOSTIC FACTORS IN PATIENTS WITH NON­
SMALL CELL LUNG CANCER
3.1 Introduction
Over the past decade a number of clinical and laboratory parameters have been 
shown to have prognostic value in patients with inoperable NSCLC.
The possibility of cure for patients with inoperable non-small cell lung cancer is 
limited as previously discussed in section 1.4.3. Median survival is known to 
decrease with increasing age, stage of disease, poor performance status, low 
haemoglobin levels, raised white cell count and hypoalbuminaemia (Numico et al., 
2001). For example, in those patients with advanced inoperable disease 
(approximately 50%), prognosis tends to be poor, and survival seldom exceeds 6-9 
months (Hespanhol et al, 1995; Espinosa et al., 1995 Naruke et al., 1997). 
Traditionally patients have been selected for active or supportive treatment 
depending on clinicopathological criteria including age, stage of disease, 
performance status, weight loss or hypoalbuminaemia (Numico et al, 2001). Other 
prognostic factors which have been associated with a reduction in survival in patients 
with advanced lung cancer include: gender, tumour type, haemoglobin and white cell 
count levels (Espinosa et al., 1995; Hespanhol et al., 1995; van Zanwijk et al, 1995; 
Palomares et al, 1996; Fu et al., 1999; Martins and Pereira, 1999; Buccheri and 
Ferrigno, 2001; Choi et al., 2001; Numico et al., 2001; Brundage et al, 2002). 
Recent reports also suggest that the systemic inflammatory response, as evidenced
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by an elevated C-reactive protein concentration, may be a significant factor in the 
survival of patients with advanced non-small cell lung cancer (Scott et al, 2002).
Oncologists have long been aware of the importance of good functional status in 
cancer patients; they routinely use a performance status score, for example the 
Kamofsky Performance Status index (KPS) or the Eastern Co-operative Oncology 
Group performance status (ECOG-ps) to measure the impact of the illness and the 
effect of any treatment that has been administered.
The Kamofsky Performance Status index (KPS) is a widely used method of 
quantifying the functional ability of the cancer patient, and has been demonstrated to 
be one of the most important prognostic factors in nearly all cancers (Kamofsky and 
Burchenal, 1949; Batel-Copel et al, 1997). It was originally designed to provide a 
measurement of the nursing workload in relation to the lung cancer patient’s 
palliative treatment. The scale is composed of an eleven point rating scale, which 
ranges from normal functioning (100) to dead (0) (Mor et al, 1984) and focuses on 
the physical performance and dependency of the patients (see Figure 3.1). Whilst it 
is recognised that brain metastases produce the greatest debilitating effect on 
functioning, these are however only moderately associated with a lower Kamofsky 
Performance Status. This perhaps highlights the subjective nature of the assessment 
of performance status, and suggests the difficulty in the interpretation of 
performance status in relation to the appropriate selection of patients for treatment. 
Indeed, a down-side of the Kamofsky Performance Status is that it has been shown 
to have an unreliable inter-rater applicability, and is dependent on the experience of 
the assessor (Ando et al, 2001). Moreover, despite the fact that it has long been
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recognised that low activity and poor physical function are important prognostic 
factors in patients with lung cancer, unless the patient is entered into a clinical trial 
this assessment tends to be neglected (Capewell and Sudlow, 1990).
The Eastern co-operative oncology group has also developed a five-point 
observation scale to assess the performance status of these patients (see Figure 3.2). 
Taylor and co-workers (1999) suggested that ECOG-ps is a simpler format for 
clinicians to utilise, as it contains a five-point scale rather than the eleven-point scale 
used in the Kamofsky Performance Status. Both these scores have been shown to be 
interchangeable; however, Buccheri and co-workers (1994) suggested that ECOG-ps 
may have better predictive validity than that of Kamofsky Performance Status. 
These performance scales attempt to quantify the patients’ actual level of function, 
ability for self-care and level of ambulation (Taylor et al, 1999). Indeed, a high 
performance status has been reported to be correlated with survival and the patient’s 
ability to tolerate treatment (Taylor et al, 1999). ECOG-ps may be considered to be 
the most simple and most reproducible scale to use to predict outcome in patients 
with non-small cell lung cancer (Espinosa et al., 1995; Taylor et al, 1999).
The physician’s assessment of a patient’s physical abilities and limitations may vary 
from the patient’s own assessment of themselves (Blagden et al, 2003). Self 
reported performance status measurement using the activities of daily living could 
therefore be used to assess functional status in cancer patients (Reuben, 1997; 
Stafford and Cyr, 1997). However, Stafford and Cyr (1997) recognised that self- 
reported health status differs in patients with and without cancer and amongst 
various cancers. Lung cancer patients had the poorest self-reported health status,
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54% rating their overall health status as fair / poor. Indeed this study indicated that 
independent of other factors, patients with cancer reported small but significant 
increases in self reported poor health and functional limitations compared to elderly 
individuals without cancer. Objective physical functional tests (e.g. chair stands, 
etc) may therefore prove to be more sensitive to such changes (Sama, 1994).
As previously recognised in section 1.6, progressive weight loss is a common 
phenomenon in patients with advanced cancer. For example, O’Gorman and co­
workers (1998) in their study of 119 patients with advanced gastrointestinal cancer 
considered the impact of weight loss on the quality of life of these patients. They 
demonstrated that weight loss was associated with lower anthropometric 
measurements, albumin concentrations and poorer performance status. Interestingly, 
they also found that 71% of the weight losing patients had an elevated C-reactive 
protein concentration, compared with 27% of weight stable patients, thus suggesting 
that an elevated C-reactive protein concentration influences the weight loss in 
patients with advanced cancer.
As previously acknowledged, the extent of disease, weight loss and performance 
status of the patient have been shown to be important prognostic factors in patients 
with advanced non-small cell lung cancer (Jeremic and Shibamoto, 1995; Brundage 
et al., 2002). However, it has also been suggested that additional factors such as 
haematological and biochemical factors may provide additional prognostic 
information, which may be useful in the selection of patients for the appropriate 
treatments (Brundage et al., 2002).
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Borges and co-workers (1996) considered various prognostic factors in the 
assessment of response to treatment in 1052 patients receiving platinum based 
chemotherapy for unresectable non-small cell lung cancer. Of the haematological 
factors considered, they reported that those patients with a haemoglobin level >12g/l 
and a white cell count <10 xl09/l were found to have higher response rates to the 
chemotherapy. Herndon and co-workers (1999), as part of their study of patients 
with advanced non-small cell lung cancer, examined the prognostic importance of 
various clinical factors. They reported that those patients who had a haemoglobin 
level <12g/l had a poorer prognosis. They also found that those patients with an 
albumin concentration of <35g/l had a poorer prognosis. Indeed, it has also been 
reported by McMillan and co-workers (2001b) that this reduction in albumin 
concentration, which is frequently observed in patients with advanced cancer, (eg. 
lung and gastrointestinal cancer) is recognised to be part of the inflammatory 
response. As the albumin concentrations fall, other acute phase proteins such a C- 
reactive protein rise (Margarson and Soni, 1998). This fall in albumin concentration 
has also been associated with a reduction in weight and reduced performance status 
in patients with advanced cancer (O’Gorman et al, 1998).
In summary, following consideration of the various prognostic factors associated 
with patients who have advanced non-small cell lung cancer, a proforma (Figure 3.3) 
was developed to identify the prognostic factors discussed during the following 
studies. This included: age, gender, stage of disease, tumour type, ECOG- 
performance status (ECOG-PS), haemoglobin, white cell count, albumin, C-reactive 
protein and treatment received.
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Figure 3.1 Kamofsky Performance Status
Condition
A. Able to carry on normal 
activity and to work. No 
special care needed
B. Unable to work. Able to 
live at home, care for most 
personal needs. A varying 
degree of assistance is 
needed
C. Unable to care for self. 
Requires equivalent of
institutional or hospital 
care. Disease may be 
progressing rapidly.
Percentage
100
90
80
70
60
50
40
30
20
10
0
Comments
Normal, no complaints, no 
evidence of disease
Able to carry on normal 
activity , Minor signs or 
symptoms of disease 
Normal activity with 
effort, some signs or 
symptoms of disease 
Cares for self. Unable to 
carry on normal activity or 
do active work
Requires occasional
assistance, but is able to 
care for most of his needs 
Requires considerable 
assistance and frequent 
medical care
Disabled, require special 
care and assistance.
Severely disabled,
hospitalisation is indicated 
although death is not 
imminent
Hospitalisation necessary, 
very sick, active support 
treatment necessary. 
Moribund, fatal processes 
progressing rapidly 
Dead
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Figure 3.2 ECOG Scale
Grade
0 Able to carry out all normal activity without restriction
1 Restricted in physical strenuous activity but ambulatory and able to carry 
out light work
2 Ambulatory and capable of all self-care but unable to carry out any work; 
up and about more than 50% of waking hours
3 Capable of only limited self-care; confined to bed or chair more than 50% 
of walking hours
4 Completely disabled; cannot carry out any self-care; totally confined to 
bed or chair
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Figure 3.3 Proforma used to collect information in patients with Non-Small Cell
Lung Cancer
Hospital Number
Patients Name
Date of Birth
Age (years)
Gender - Male/Female
Date of Diagnosis
Date of Death
Tumour
Tumour Type
(Squamous/ Adenocarcinoma/ Large Cell/ Other)
Stage of Disease (1/11/ IIIA/ IIIB/ IV)
ECOG Performance Status (0/1/2/3/ 4)
Haemoglobin (g/1)
White cell count (10xl0y/l)
Albumin (g/1)
C-reactive protein (mg/1)
Treatment (active / palliative)
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4. PATIENT STUDY: BODY COMPOSITION PARAMETERS AND 
PERFORMANCE STATUS IN PATIENTS WITH INOPERABLE 
NON-SMALL CELL LUNG CANCER
4.1 Introduction
Physical function as assessed by performance status remains an important predictor 
of response to treatment in patients with non-small cell lung cancer, NSCLC (Conill, 
et al, 1990; Firat et al, 2001; Hensing et al, 2003). It has been long recognised 
that, in patients with cancer, reduction in physical function is associated with the loss 
of protein mass, in particular skeletal muscle. Simple techniques such as height, 
weight and skinfold anthropometry may be used in this assessment (Ferrigno and 
Buccheri, 2000; McMillan et al, 2002; Kamimura et al, 2003). Recently, McMillan 
and co-workers (2001b) proposed that, in advanced cancer patients, albumin 
concentrations are primarily determined by the protein mass of the body (as 
estimated by total body potassium) and the systemic inflammatory response (as 
estimated by C-reactive protein). They also suggested that the systemic 
inflammatory response is a major factor in the erosion of protein mass in the body.
The aim of the present study was to examine the relationship of ECOG performance 
status (ECOG-ps), anthropometric and blood parameters in patients with inoperable 
NSCLC.
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4.2 Materials and Methods
4.2.1 Subjects
Fifty patients with inoperable non-small cell lung cancer from a multidisciplinary 
clinic within a single institution (Royal Infirmary, Glasgow) were included in the 
study. Patients were either receiving supportive care only, or were prior to receiving 
chemotherapy or radiotherapy.
4.2.2 Experimental design
Patients were assessed on an outpatient basis. At the clinic visit ECOG-ps together 
with height, weight, biceps, triceps skinfold thickness and mid-upper arm 
circumference measurements were carried out and a blood sample was taken for 
analysis of albumin and C-reactive protein.
The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary. All patients were informed of the purpose of the study and all gave 
written informed consent.
4.2.3 Analytical Methods
Height and weight: These patients’ details were obtained as detailed in section
2.2.1. These measurements were then used to calculate the body mass index:
Body Mass Index (KG/M2) = Weight (kg) -s- Height2 (m2)
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Performance Status: This assessment was undertaken using the ECOG-ps (as 
described in Section 3.1) to assess the functional ability of patients. This is a five- 
point scale, which is scored 0 - 4  depending on the level of functional independence 
achieved by the patient (see Figure 3.2).
Skinfold anthropometry : this was performed as detailed in Section 2.2.2. The sites 
measured included biceps, triceps and mid-upper arm circumference.
Blood parameters: Venous blood samples were taken from each patient for routine 
laboratory measurements of C-reactive protein and albumin. Albumin was measured 
by a BCG dye-binding method and C-reactive protein was measured using a 
turbidometric assay after binding to a specific antibody on an Advia 1650 analyser 
(Bayer Corporation, Tarrytown, NY, USA). For C-reactive protein the limit of 
detection was 5 mg/1. The inter-assay coefficient of variation was less than 3% and 
5% over the sample concentration range for albumin and C-reactive protein 
respectively.
4.2.4 Statistics
Data are presented as median and range. Where appropriate, comparison of patient 
groups was carried out using the Kruskal-Wallis test for analysis of variance. 
Analysis was performed using the SPSS software package (SPSS, Chicago,IL).
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4.3 Results
Fifty patients (33 males and 17 females) with inoperable non-small cell lung cancer 
were studied. The clinical characteristics of the patients included in the study are 
detailed in Table 4.1. The majority of patients were male (66%), over the age of 60 
years, had a BMI, skinfold anthropometry and albumin concentrations in the normal 
range. The majority of patients had an elevated C-reactive protein concentration and 
an ECOG performance status of 1.
Patients were grouped according to ECOG-ps (Table 4.2). With a poorer 
performance status there was a lower BMI (p<0.05), biceps skinfold thickness 
(p<0.05), triceps skinfold thickness (p<0.05), mid-upper arm circumference (p<0.01) 
and albumin concentrations (p<0.01).
4.4 Discussion
Conventionally, the selection of inoperable cancer patients for active or supportive 
treatment has been based on clinicopathological criteria, including age, stage, 
performance status, weight-loss or hypoalbuminaemia (Numico et al, 2001). 
However, the limitations of weight loss are well recognised (see section 2.1). In 
contrast, performance status is a useful global assessment of function and has been 
used to aid the selection of patients for treatment, stratification into clinical trials, 
measurement of the efficacy of new therapies and to assess the prognosis of patients 
with advanced cancer. However, the assessment of performance status may be 
subjective. For example, significant differences in the assessment of performance 
status have been reported between oncologists, nurses and patients, oncologists being 
the most optimistic in their assessment and patients the least (Ando et al, 2001).
In the present study mid-upper arm circumference was shown to be strongly 
associated with ECOG-ps in patients with advanced non-small cell lung cancer. 
These results are consistent with the previous strong correlation between mid-upper 
arm circumference and Kamofsky performance status in patients with advanced 
gastrointestinal cancer (McMillan et al, 2002) and would support the concept that 
mid upper arm circumference primarily reflects lean tissue and that it is the loss of 
such tissue that determines performance status in advanced cancer.
In the present study it was of interest that albumin concentrations were also strongly 
associated with ECOG-ps. However, in the present study there was less variation in 
the measurement of albumin concentrations compared with that of mid upper arm
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circumference. Therefore, it may be that the measurement of albumin offers a better 
standardised method of measuring the loss of lean tissue and physical function in the 
patient with advanced non-small cell lung cancer.
It has recently been proposed that the combination of albumin and C-reactive protein 
may form the basis of a useful standardised and non-subjective assessment of 
outcome in patients with advanced cancer (McMillan et al., 2001a). On the basis of 
the results of the present study a comparison of such an assessment with ECOG-ps is 
worthy of further study in patients with inoperable non-small cell cancer.
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Table 4.1. Characteristics of patients with inoperable non-small cell lung cancer
Age (yr)
Gender (male/ female)
BMI (kg/m2)
Triceps skinfold thickness (mm) 
Biceps skinfold thickness (mm) 
Mid-upper arm circumference (cm) 
Albumin (g/1)
C-reactive Protein (mg/1)
Stage (III/ IV)
ECOGPS (0/1/2)
Patients 
(n= 50)
66 (43-78) 
33/17
23.8 (14.2-33.6) 
12 (2.2-23) 
8.8 (2 .2- 21 .2) 
26.6(17-32)
40 (31-45)
38 (<6-258)
23/27
13/27/10
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Table 4.2. The relationship between ECOG-ps, anthropometric and blood 
parameters in patients with inoperable non-small cell lung cancer.
Age, yrs
Gender (male/ female)
BMI (kg/m2) 
Triceps skinfold 
thickness (mm) 
Biceps skinfold 
thickness (mm) 
Mid-upper arm 
circumference (cm) 
Albumin (g/1) 
Albumin >35 g/1 
<35 g/1
C-reactive protein 
<10 mg/1 
>10mg/l 
Stage (III/ IV)
ECOG-ps 0 
(n=13)
65 (45-74) 
9 /4
27.7 (21 -30.8)
15.8(6.4-23)
10.2 (5.6-18)
28 (24-30)
42 (38-44)
13
0
16 (<6 -  163)
5
8
8 /5
ECOG-ps 1 
(n=27)
66 (43 -  78)
19/8
23.7 (14.2-33.6)
12(3.6-21.8)
8.8 (3.4-21.2)
26.6 (17-32)
40 (32-45)
26
1
42 (<6 -  258)
3
24
11/16
ECOG-ps 2 
(n=10)
73 (61 -78 ) 
5 /5
21 (14.2-32.5)
8.7 (2.2-13.2)
5.4(2.2-15.2)
24.3(19-30) 
37 (31-41)
7
3
67 (<6-116)
3
7
4 /6
C-reactive Protein (mg/1)
p-Value
0.070
0.496
0.029
0.022
0.013
0.009
0.002
0.015
0.258
0.117
0.433
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5 PATIENT STUDY: EVALUATION OF A CUMULATIVE
PROGNOSTIC SCORE BASED ON THE SYSTEMIC
INFLAMMATORY RESPONSE IN PATIENTS WITH NON-SMALL
CELL LUNG CANCER
5.1 Introduction
Since the 1930’s lung cancer has increased in incidence to become the most
frequently diagnosed neoplasm in the western world, accounting for 80% of all 
pulmonary tumours. Lung cancer kills more people than any other cancer and its 
incidence is on the rise (Souhami and Tobias, 1998). Non-small cell lung cancer 
constitutes approximately three quarters of all histological types of lung cancer 
deaths world-wide (Ihde and Minna, 1991; Hespanhol et al, 1995; Juretic et al, 
1999; Ferrigno and Buccheri, 2000). Mateva and co-workers (1999) demonstrated 
that early diagnosis of lung cancer is of crucial importance for surgical management 
and prognosis of lung cancer patients. However, due to the aggressive nature of this 
tumour type most patients present with advanced inoperable disease (approximately 
50%) and consequently the survival of these patients is extremely poor (Splinter, 
1991; Hespanhol et al, 1995; Juretic et al, 1999; Ferrigno and Buccheri, 2000).
Conventionally, the selection of these patients for active or supportive treatment has 
been based on certain clinico-pathological criteria, including age, stage, performance 
status, weight loss or hypoalbuminaemia (Gomm et al, 1990; Espinosa et al, 1995; 
Katsumata et al, 1996, Palomares et al, 1996; Charloux et al, 1997; Wigren et al,
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1997, Fu et al, 1999; van Dijck et al, 2001, Plataniotis and Theofanopoulou, 2001, 
Numico et al, 2001).
In order to assess the value of pre-treatment characteristics in patients with 
inoperable non-small cell lung cancer who were treated with platinum based 
combination chemotherapy, Paesmans and co-workers (1997) prospectively 
collected data on 23 pre-treatment variables and objective response following three 
cycles of chemotherapy in 1052 patients who were registered into a clinical trial of 
the European Lung Cancer Working Party between December 1980 and August 
1991.
Pre-treatment variables included -  sex, age, loss of body weight, histology, prior 
therapy, Kamofsky performance status, extent of disease, type of lesion, white blood 
cell count, neutrophil count, platelet count, haemoglobin, alkaline phosphate, 
bilirubin, creatinin, lactate dehydrogenase, calcium, evidence of metastases. The 
results of this study highlighted that an overall response to treatment is the strongest 
marker of prolonged survival, and they also suggested further prognostic information 
could be improved by using pre-treatment therapeutic markers of full blood count, 
Kamofsky Perfomance Status and extent of disease.
Similarly, Hesphanhol and co-workers (1995) undertook a prospective study of 411 
patients between 1984 and 1990. They reported that, on both univariate and 
multivariate analysis poor performance status, weight loss (>10%) and 
hypoalbuminemia (<35 g/1) were poor prognostic factors. These results highlight the
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predictive value of performance status, weight loss and serum albumin, when 
combined with TNM staging classification.
Recent studies have shown that the presence of a systemic inflammatory response, as 
evidenced by increased circulating concentrations of C-reactive protein, is a 
prognostic factor independent of age, stage, the presence or absence of weight-loss 
and performance status in patients with advanced cancer including NSCLC (Martins, 
et al, 1999; O’Gorman et al, 2000; Mahmoud and Rivera, 2002; Scott et al, 2002).
Scott and co-workers (2002) examined 106 patients with inoperable NSCLC 
(between January 1995 and November 1998), observing the extent to which weight 
loss, albumin and C- reactive protein concentrations, performance status and quality 
of life impacted on the survival of these patients. Patients were grouped according to 
the extent of the systemic inflammatory response, <10, 11 - 100 and >100mg/l. An 
increase in the systemic inflammatory response was associated with increased weight 
loss, reduction in haemoglobin and albumin concentrations, and a reduced 
performance status. They also found that survival was affected by the magnitude of 
the systemic inflammatory response: in those patients with C-reactive protein 
concentrations <10mg/l, survival time was 11 months, whilst in those patients with 
C-reactive protein concentrations >100mg/l survival time was poor at only three 
months. The results of this study highlighted that the greater the magnitude of the 
systemic inflammatory response, the greater the weight loss, the poorer the 
performance status, and the poorer the survival.
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The aim of the present study was to assess the value of combining C-reactive protein 
and recognised prognostic factors as stage, performance status and 
hypoalbuminaemia to form new prognostic scores for patients with inoperable non­
small cell lung cancer.
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5.2 Materials and Methods
5.2.1 Study Design
Patients with inoperable non-small cell lung cancer (stage III and IV) who presented 
at the multidisciplinary oncology clinic in Glasgow Royal between January 1997 and 
October 2002 were included in the study. Data for 1997 -  1999 were collected 
retrospectively and that for 2000 -  2002 prospectively. All patients had to have 
cytologically or histologically confirmed disease and were staged according to the 
American Thoracic Society TNM classification on the basis of clinical findings, 
chest X-ray, and where appropriate, bronchoscopy, liver ultrasound, isotope bone 
scan and computerised tomography of the thorax (Mountain, 1991).
Clinical stage, tumour type and ECOG performance status were recorded at time of 
diagnosis. A blood sample was also obtained for measurement of haemoglobin, 
white cell count, and C-reactive protein concentrations. Patients were considered to 
have undergone active treatment if they received chemotherapy (mainly cisplatin 
based) and / or radical radiotherapy. Patients receiving palliative radiotherapy and / 
or palliative care (symptom control) were considered to have had supportive 
treatment.
The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary.
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5.2.2 Methods
Blood parameters: Routine laboratory measurements of haemoglobin, white cell 
count, and C-reactive protein concentration were carried out as previously described 
in Section 4.2.3. The coefficient of variation for these methods, over the range of 
measurement, was less than 10% as established by routine quality control 
procedures.
5.2.3 Statistics
Data are presented as median and range. Grouping of the continuous variables, age, 
haemoglobin and white cell count was carried out as previously described (Vincent 
et al, 1987; Paesmans et al, 1995; Herndon et al, 1999). C-reactive protein 
concentrations were also grouped (<10/>10mg/l) as previously described (O’Gorman 
et al, 2000; McMillan et al, 2001a).
Prognostic scores were constructed by assigning one point for each of the following 
criteria: stage IV, ECOG-ps 2-4, albumin <3 5g/1 and C-reactive protein >10mg/l. 
Cumulative scores were obtained by combining C-reactive protein with each of the 
other variables. For example, patients with hypoalbuminaemia (<35g/l = 1) and an 
elevated C-reactive protein (>10mg/l =1) were assigned a score of two.
Univariate survival analysis was performed using the Kaplan-Meier method. 
Multivariate survival analysis and calculation of hazard ratios (HR) were performed 
using Cox regression analysis with prognostic scores as covariates. Deaths up to
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31st March 2003 were included in the analysis. Analysis was performed using SPSS 
software (SPSS Inc., Chicago, Illinois, U.S.A.).
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5.3 Results
261 patients were initially identified as being suitable for inclusion in the study (119 
patients from 1997 -  1999, 142 patients from 2000 -  2002), as they had been 
diagnosed with advanced inoperable non-small cell lung cancer. Common to all 
studies which include both retrospective and prospective data, missing data meant 
that some patients had to be excluded from the final analysis. The majority of 
patients (50 patients between 1997 -  1999 and 45 patients between 2000 -  2002) 
were excluded because performance status was not documented in the medical 
records. Two patients were excluded as no date of diagnosis was available, a further 
two patients were excluded as no C-reactive protein or albumin level was available, 
and one patient was lost to follow up. One hundred and sixty one patients were 
therefore included in the final analysis.
The characteristics of patients with inoperable NSCLC (n= 161) are shown in Table
5.1. The majority were male, over the age of 60 years, had stage IV disease and had 
good performance status. Approximately, 20% had hypoalbuminaemia and 80% had 
an elevated C-reactive protein concentration. One third of patients received active 
treatment (64% received cisplatin based chemotherapy); the remaining patients 
received supportive treatment.
One hundred and eighteen (73%) of patients died during the follow-up period. On 
univariate survival analysis, stage (p<0.05), tumour type (p<0.01), ECOG-ps 
(p<0.001), white cell count (p<0.01), albumin (p<0.001) and C-reactive protein (p 
<0.01) were significant predictors of survival. On multivariate survival analysis, all
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these variables, with the exception of white cell count, remained significant 
independent predictors of survival.
The relationship between the prognostic scores based on the combinations of C- 
reactive protein with stage, ECOG-ps and albumin respectively and the median 
survival is shown in Table 5.2. All these prognostic scores had hazard ratios in the 
range 1.7-2.0 which was comparable with that for the score based on the 
combination of stage and ECOG-ps.
When the three scores based on the combinations of the systemic inflammatory 
response and stage, ECOG-ps and albumin were compared with the combination of 
stage and ECOG-ps, only the score based on the combination of the systemic 
inflammatory response and albumin (HR 1.70, 95%CI 1.23-2.35, p=0.001) and the 
score based on stage and ECOG-ps (HR 1.48, 95%CI 1.12-1.95, p=0.006) retained 
independent significance.
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5.4 Discussion
Despite well documented evidence that performance status is an important prognostic 
factor for survival in patients with non small cell lung cancer (Paesmans et al, 1995; 
Ando et al, 2001), many patients within this study had to be excluded as no 
performance status was recorded in their medical records. It is likely that the study 
cohort excludes more patients who received supportive care only, since those patients 
who received active treatment were most likely to have had their performance status 
recorded during their treatment.
In the present study, both the established indicators of the presence of a systemic 
inflammatory response, white cell count and C-reactive protein, were predictive of 
survival in patients with inoperable NSCLC. This is consistent with previous studies, 
which have shown that a raised white cell count (Paesmans et al, 1997) and C-reactive 
protein concentrations (Scott et al, 2002), have prognostic value, independent of stage, 
in patients with inoperable NSCLC.
When C-reactive protein concentrations were combined with stage, ECOG-ps and 
albumin to form new prognostic scores, these combined scores improved the 
prediction of survival based on stage, ECOG-ps or albumin alone. Indeed, in each of 
the cumulative scores, the presence of an elevated C-reactive protein was associated 
with a halving of survival. Furthermore, when these three combinations were 
compared to the conventional combination of stage and ECOG-ps, the combination 
of the systemic inflammatory response and albumin and the conventional clinical 
combination stage and ECOG-ps were found to have comparable prognostic value.
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These results are consistent with the evidence that chronic activation of the systemic 
inflammatory response is detrimental to the outcome of patients with NSCLC, being 
associated with an increase in weight loss (Staal-van den Brekel et al, 1995; Scott et al, 
1996) and fatigue (Scott et al, 2003), loss of lean tissue (McMillan et al, 1998; Simons 
et al, 1999), decreased performance status and survival (Martins et al, 1999; Scott et 
al, 2002).
The mechanism by which a systemic inflammatory response is evoked in patients 
with NSCLC is not clear. One possibility is that since many patients have co­
existing pulmonary infection, the resultant increase in white blood cells would lead 
to increased pro-inflammatory cytokine release and a subsequent increase in 
circulating C-reactive protein concentrations. However, in this study, although the 
white cell count was significantly correlated with C-reactive protein concentrations 
the magnitude of the relationship was small (r2 less than 15%). This would suggest 
that infection was not the main stimulus to the increased C-reactive protein 
concentrations.
An alternative explanation would be that pro-inflammatory cytokines are produced 
by the tumour. Indeed, there is evidence that pro-inflammatory cytokines are 
produced locally by tumours in patients with NSCLC (Arias-Diaz et al, 1994). In 
particular, interleukin-6 is recognised as a primary mediator of increased C-reactive 
protein concentrations in these patients (Yanagawa et al, 1995; Scott et al, 1996). 
However, whether interleukin-6 is produced directly by lung cancer cells remains 
unclear.
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In conclusion, the results of the present study showed that a cumulative score based on 
C-reactive protein and albumin provides comparable prognostic information to that of 
conventional prognostic criteria. However, the cumulative score based on C-reactive 
protein and albumin (Glasgow Prognostic Score) has the advantage that of being simple 
to measure, routinely available and well standardised.
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Table 5.1 Clinical characteristics and survival in patients with inoperable NSCLC:
Univariate survival analysis
Patients Survival (months)
161 (100%) Median (95% Cl)
Age <60 yrs 37 (23) 10.3 (8.2-12.4)
>60 yrs 124 (77) 8.2 (6.1-10.3)
Sex: Male 105 (65) 9.1 (6.6-11.6)
Female 56 (35) 8.9 (5.9-11.8)
Stage III 57 (35) 12.0 (8.1-15.9)
IV 104 (65) 6.9 (4.0-9.9)
Type Squamous 64 (40) 9.7 (5.9-13.5)
Adenocarcinoma 53 (33) 9.0 (2.6-15.3)
Other 44 (27) 3.9 (0.2-7.9)
ECOG-ps 0-1 91 (57) 12.0 (8.7-15.4)
2-4 70 (43) 4.2(1.6-6.7)
Haemoglobin >12 g/1 101 (63) 9.1 (6.3-11.9)
<12 g/1 60 (37) 8.9 (6.4-11.3)
White Cell Count <1 Ox 109/l 82 (51) 12.4 (7.9-16.9)
>10xl09/l 79 (49) 6.5 (2.9-10.0)
Albumin >35 g/1 126(78) 10.1 (7.4-12.8)
<35 g/1 35 (22) 3.7 (2.3-5.1)
C-reactive protein <10 mg/1 29 (18) 16.4 (11.0-21.7)
>10 mg/1 132 (82) 7.1 (4.9-9.3)
P value
0.593
0.810
0.015
0.003
<0.001
0.187
0.003
<0.001
0.003
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Table 5.2 Cumulative prognostic scores and survival in patients with inoperable
NSCLC (n=161)
C R P /  s ta g e  ( n )  C R P
C R P /  E C O G - p s
14
15 
4 3  
8 9
2 3
6
68
6 4
C R P /  a lb u m in
< 1 0 m g / l
> 1 0 m g / l
C R P
< 1 0 m g / l
> 1 0 m g / l
C R P
S ta g e
I I I
I V
I I I
IV
E C O G - p s
0-1
2 -4
0-1
2 -4
A lb u m in
C u m u la t iv e
s c o re s
0
1
1
2
S u r v iv a l  
( m o n th s )  
1 8 .2 ( 1 4 .5 - 2 1 .9 )  
1 0 .4  ( 7 .9 - 1 2 .8 )  
8 .9  ( 5 .5 - 1 2 .3 )
6 .1  ( 3 .4 - 8 .7 )
1 7 .9 ( 1 5 .5 - 2 0 .3 )
9 . 0 ( 4 .3 - 1 3 .6 )
4 .2  ( 2 .2 - 6 .2 )
2 7
2
9 9
3 3
S ta g e /  E C O G - p s
< 1 0 m g / l
> 1 0 m g / l
S ta g e
4 0  I I I  
17
51  I V  
5 3
> 3 5 g / l
< 3 5 g / l
> 3 5 g / l
< 3 5 g / l
E C O G - p s
0-1
2 -4
0-1
2 -4
1 7 .0 ( 1 1 .4 - 2 2 .6 )
8 .9  ( 6 .3 - 1 1 .4 )
3 .9  ( 0 .8 - 7 .1 )
1 6 .1  ( 9 .5 - 2 2 .6 )  
9 .7 ( 3 .5 - 1 5 .8 )  
1 0 .4  ( 5 .8 - 1 4 .9 )  
3 .6 ( 1 . 7 - 5 . 6 )
CRP C-reactive protein, median survival (95% Cl)
H a z a r d  r a t io  
( 9 5 % C I )
1 .7 3 ( 1 .2 3 - 2 .3 3 )
p < 0 .0 0 1
1 .7 9 ( 1 .3 7 - 2 .3 5 )
p < 0 .0 0 1
2 .0 0 ( 1 .4 7 - 2 .7 0 )
p O . 0 0 1
1 .7 3 ( 1 .3 3 - 2 .2 4 )
pO.001
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6 PATIENT STUDY: COMPARISON OF AN INFLAMMATION BASED
PROGNOSTIC SCORE WITH PERFORMANCE STATUS IN
PATIENTS UNDERGOING CHEMOTHERAPY FOR INOPERABLE 
NON-SMALL CELL LUNG CANCER
6.1 Introduction
As noted previously, non-small cell lung cancer is the most common cause of cancer 
death in North America and Western Europe. Most patients present with advanced 
inoperable disease, with only one fifth of patients being suitable for radical 
treatment. Consequently the prognosis of these patients is extremely poor, with over 
two-thirds of patients dying within the first year of diagnosis (Espinosa et al, 
1995;Hespanhol et al, 1995; Numico et al, 2001; Kosmidis, 2002).
In the majority of patients treatment is aimed at palliation of symptoms,
improvement of quality of life and prolongation of survival. The incidence of these 
symptoms may vary at the time of diagnosis, with 80% of patients experiencing 
symptoms in the terminal phase of their illness (Numico et al, 2001). These 
symptoms include, breathlessness, anorexia, asthenia and cough.
The survival benefit gained by conventional treatments such as chemotherapy and / 
or radiotherapy, is modest and translates into limited survival prolongation (Numico 
et a l,2001). Survival rates in these inoperable patients remain extremely poor; 
indeed in those patients with advanced disease who receive best supportive care, 
only 10% will survive one year, more than 70% of patients experience local
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progression and the majority die with distant disease (Kosmidis, 2002). A meta­
analysis of chemotherapy in NSCLC patients (which included Cisplatin-based 
chemotherapy) suggested that chemotherapy regimes have an absolute advantage in 
terms of one year survival of 10% (NSCLC collaborative group, 1995), with a gain 
in the median survival estimated at two months, when compared to best supportive 
care (Klastersky and Paesmans, 2001; Belani and Langer, 2002).
However, for some patients active treatment with chemotherapy is inappropriate. In 
such cases patients are treated with best supportive care in an attempt to improve 
their symptoms. Best supportive care has been defined by Thatcher and co-workers 
(1997) as “any palliative therapeutic modality that may be offered to a patient with 
non-small cell lung cancer excluding chemotherapy but including radiotherapy and 
non-cytotoxic medications.” It has been reported by Numico and co-workers (2001) 
that in patients receiving palliative radiotherapy for the palliation of local symptoms 
such as thoracic pain and haemoptysis, this is achieved in 60 -  80 % of cases. They 
also reported that general symptoms (for example, malaise, anorexia, weight loss and 
asthenia) are only partially improved. The median duration of such palliations is 7 — 
14 weeks.
Conventionally, the selection of patients for chemotherapy has been based on 
clinico-pathological criteria, including age, stage and performance status (Numico et 
al, 2001). However, the assessment of performance status may be subjective (Ando 
et al., 2001).
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In Chapter 5, in an unselected cohort of patients with inoperable NSCLC, an 
inflammation-based prognostic score, the Glasgow Prognostic Score (GPS), was 
shown to have similar prognostic value to that of stage and ECOG performance 
status. The question of whether the GPS would be useful in the selection of 
appropriate treatment for patients with inoperable NSCLC remains to be determined.
The aim of this study was to assess the prognostic value of the GPS in patients 
receiving chemotherapy for inoperable NSCLC.
I l l
6.2 MATERIALS AND METHODS
6.2.1 Study Design
Patients presenting with inoperable NSCLC (stage III and IV) to a single multi­
disciplinary oncology clinic in Glasgow Royal Infirmary between March 2000 and 
June 2003 were studied prospectively. All patients had cytologically or 
histologically confirmed disease and were staged on the basis of clinical findings, 
chest X-ray, and where appropriate, bronchoscopy, liver ultrasound, isotope bone 
scan and computerised tomography of the thorax, according to the American 
Thoracic Society TNM classification (Mountain, 1991).
Clinical stage, tumour type and ECOG-ps were recorded at time of diagnosis. A 
blood sample was also obtained for measurement of white cell count, albumin and C- 
reactive protein concentrations. Patients received between one and six cycles of 
platinum-based chemotherapy.
The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary.
6.2.2 Methods
Blood parameters: Routine laboratory measurements of white blood cell count,
albumin and C-reactive protein concentration were carried out. The coefficient of
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variation for these methods, over the range of measurement, was less than 10% as 
established by routine quality control procedures.
The GPS was constructed as previously described in Chapter 5. Briefly, 
hypoalbuminaemia (<35 g/1 = 1 ) and an elevated C-reactive protein (>10mg/l = 1) 
were combined to form a cumulative prognostic score (0,1, 2).
6.2.3 Statistics
Data are presented as median and range. Grouping of the variables age, tumour type, 
ECOG-ps and white cell count was carried out using standard thresholds (Paesmans 
et al., 1997; Herndon et al, 1999).
Univariate survival analysis was performed using the Kaplan-Meier method. 
Multivariate survival analysis and calculation of hazard ratios (HR) were performed 
using Cox regression analysis with prognostic scores as covariates. Deaths up to 
31st October 2003 were included in the analysis. Analysis was performed using 
SPSS software (SPSS Inc., Chicago, Illinois, U.S.A.).
113
6.3 Results
The characteristics of patients with inoperable NSCLC receiving platinum-based 
chemotherapy (n= 109) are shown in Table 6.1. The majority were male and over 
the age of 60 years. Approximately, 50% had stage III disease, 90% had an ECOG- 
ps of 0-1, 75% had an elevated C-reactive protein and 10% had hypoalbuminaemia. 
Of the 69 patients with a GPS of 1 only 13 patients had hypoalbuminaemia. The 
majority (68%) received cisplatin-based chemotherapy and the remainder 
carboplatin-based chemotherapy.
Seventy one (65%) of patients died during the follow-up period. On univariate 
survival analysis, both white cell count (HR 1.67, 95% Cl 1.05 -  2.67, p<0.05) and 
GPS (HR 1.88, 95% Cl 1.25 -  2.84, p<0.01) were significant predictors of survival. 
On multivariate analysis only GPS (HR 1.77, 95% Cl 1.16 -  2.69, p=0.008) was a 
significant independent predictor of survival.
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6.4 Discussion
The results of the present study show that an inflammation-based prognostic score, the 
GPS, is superior to ECOG-ps in predicting outcome following platinum-based 
chemotherapy for inoperable non-small cell lung cancer. The median survival of 
patients with a GPS of 0, 1 and 2 were approximately 17 months, 12 months and 7 
months respectively. This suggests that the GPS may be useful in the selection of these 
patients for chemotherapy.
The reasons for the superiority of the GPS over ECOG-ps in predicting outcome in 
these patients are not altogether clear. It may be because the assessment of 
performance status is subjective and reflects functional status at a specific point in 
time. In contrast, the GPS, based as it is on the presence of an ongoing systemic 
inflammatory response and hypoalbuminaemia, predicts the progressive nutritional 
decline of the patient (McMillan et al., 2001a; Scott et al, 2002). Indeed, it has long 
been recognised that weight loss is associated with poor tolerance to chemotherapy 
(Chlebowski et al., 1996; Paesmans et al, 1997).
More recently, it has been reported that Cytochrome P450 3A activity, the principal 
drug metabolising enzyme in a variety of chemotherapeutic agents including 
cisplatin and carboplatin, is compromised in advanced lung cancer patients with an 
elevated C-reactive protein concentration (Rivory et al, 2002; Slaviero et al, 2003).
One might therefore postulate that the presence of a systemic inflammatory response 
would be associated with increased toxicity in patients receiving platinum-based 
chemotherapy. It was therefore of interest that 40% of patients with a GPS of 0
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received six cycles platinum based chemotherapy compared with 9% of those with a 
GPS of 1 (p<0.05). This suggests that the presence of a systemic inflammatory 
response may be an important factor in determining the ability of patients to tolerate 
platinum-based chemotherapy.
Moreover, in view of the importance of the systemic inflammatory response in 
determining outcome in patients with inoperable NSCLC, it may be that the addition 
of anti-inflammatory agents would provide additional therapeutic benefit.
Conventionally, in patients with inoperable NSCLC, the decision of whether or not 
to offer chemotherapy is primarily based on performance status. However, the 
toxicity, inconvenience and cost of chemotherapy has led many physicians to 
question whether chemotherapy is better than best supportive care or other palliative 
treatment in patients with inoperable NSCLC (Adelstein et al, 1995; Klatersky and 
Paesmans, 2001). The results of the present prospective study indicate that the GPS 
adds value as a guide to the selection of appropriate patients with inoperable non­
small cell lung cancer for platinum-based chemotherapy.
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Table 6.1 Clinical characteristics and survival in patients with inoperable
NSCLC receiving platinum-based chemotherapy: Univariate survival analysis
Patients Survival (months) P value
109 (100%) Median (95% Cl)
Age <60 yrs 41 (38) 10.6 (3.8-17.3)
>60 yrs 68 (62) 13.5 (11.2-15.9) 0.681
Sex: Male 63 (58) 15.1 (11.0-19.2)
Female 46 (42) 10.6(10.1-11.1) 0.434
Stage III 52 (47) 13.5 (9.1-18.0)
IV 57 (52) 12.2 (7.8-16.6) 0.338
Type Squamous 40 (37) 15.1 (7.9-22.4)
Adenocarcinoma 46 (42) 14.0 (9.5-18.6)
Other 23 (21) 11.7 (9.7-13.6) 0.098
ECOG-ps 0 29 (27) 16.0 (9.2-22.7)
1 71 (65) 12.2 (9.9-14.5)
2 9(8) 7.1 (1.7-12.4) 0.181
White Cell Count <10x109/l 62 (56) 16.6(13.1-20.1)
>10 xl09/l 47 (44) 11.7 (9.4-14.0) 0.031
GPS 0 27 (25) 17.0(14.0-19.9)
1 69 (63) 12.1 (10.0-14.1)
2 13 (12) 7.1 (4.9-9.2) 0.002
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Figure 6.1a The relationship between ECOG performance status ( 0  , 1
, 2 ____ ) in patients with inoperable non-small cell lung cancer receiving
platinum-based chemotherapy
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Figure 6.1b The relationship between the GPS ( 0  , 1 , 2 ____ ) in
patients with inoperable non-small cell lung cancer receiving platinum-based 
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7. PATIENT STUDY: A PROSPECTIVE EVALUATION OF AN
INFLAMMATORY BASED PROGNOSTIC SCORE (GPS) IN
PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG
CANCER
7.1 Introduction
As noted previously, non-small cell lung cancer (NSCLC) accounts for approximately 
three quarters of all lung cancers, and is recognised to be the most common cause of 
cancer related death in North America and Western Europe (Hespanhol et al., 1995; 
Kosmidis, 2002). Most patients present with inoperable disease, and die within 12 
months of diagnosis. For the majority, treatment tends to focus on palliating symptoms, 
improvement of quality of life and prolongation of survival (Numico et al, 2001).
Radical radiotherapy and platinum-based chemotherapy have been shown to benefit 
some patients (Klastersky and Paesmans, 2001). Conventionally, such patients are 
selected for active treatment on the basis of stage and performance status (Numico et al,
2001). Performance status is widely utilised in oncology practise as it has been found to 
correlate well both with response to treatment and survival (Blagden et al, 2003). 
Assessment of performance status is however recognised to be subjective, physicians, 
nurses and patients differing in their assessment (Ando et al, 2001).
Ando and co-workers (2001), in their study of 206 patients with stage III and IV disease 
asked patients to score their own performance status and compared this to scores 
performed by nurses and oncologists. The oncologist were found to be most optimistic,
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while the patients were found to be most pessimistic. Performance status scored by the 
oncologist was found to correlate most closely with survival. The authors concluded 
that oncologists were better at evaluating performance status than the patients 
themselves. This nonetheless highlights the subjective nature of this method of 
assessment. Possibly a more objective measurement might be of more benefit in the 
selection of patients for appropriate treatment.
It has been shown in Chapter 5, using an unselected cohort of patients with 
inoperable NSCLC, that an inflammation-based prognostic score, the Glasgow 
Prognostic Score (GPS), had similar prognostic value to that of stage and ECOG 
performance status (ECOG-ps). Furthermore, this new prognostic score, is an 
objective assessment, based as it is on the measurement of C-reactive protein and 
albumin, appeared to be superior in predicting survival in patients receiving 
platinum-based chemotherapy (Chapter 6).
The aim of this study was to prospectively assess the value and reliability of the GPS 
and ECOG-ps in predicting survival in patients with inoperable NSCLC who were 
treated in another centre.
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7.2 Materials and methods
7.2.1 Study Design
Patients presenting with inoperable NSCLC (stage III and IV) at Wishaw General 
Hospital, Lanarkshire between October 2002 and September 2003 were studied 
prospectively. All patients had cytologically or histologically confirmed disease and 
were staged on the basis of clinical findings, chest X-ray and, where appropriate, 
bronchoscopy, liver ultrasound, isotope bone scan and computerised tomography of 
the thorax, according to the American Thoracic Society TNM classification 
(Mountain, 1991).
Clinical stage, and ECOG-ps were recorded at time of diagnosis. ECOG-ps were 
assessed by the respiratory physicians. A blood sample was also obtained for 
measurement of white cell count, haemoglobin, albumin and C-reactive protein 
concentrations. Patients were considered to have undergone active treatment if they 
received chemotherapy (mainly cisplatin based) and / or radical radiotherapy. 
Patients receiving palliative radiotherapy and / or palliative care (symptom control) 
were considered to have had supportive treatment.
The study was approved by the Research Ethics Committee of Wishaw General 
Hospital.
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7.2.2 Methods
Blood parameters: Routine laboratory measurements of haemoglobin, white cell
count, albumin and C-reactive protein concentration were carried out. The 
coefficient of variation for these methods, over the range of measurement, was less 
than 10% as established by routine quality control procedures.
The GPS was constructed as previously described in Chapter 5. Briefly, patients 
with both an elevated C-reactive protein (>10mg/l) and hypoalbuminaemia (<35g/1) 
were allocated a score of 2. Patients in whom only one of these biochemical 
abnormalities was present were allocated a score of 1. Patients in whom neither of 
these abnormalities was present were allocated a score of 0.
7.2.3 Statistics
Univariate survival analysis was performed using the Kaplan-Meier method with the 
logrank test. Multivariate survival analysis and calculation of hazard ratios (HR) 
were performed using Cox regression analysis with stratification by centre. Deaths 
up to 31st March 2004 were included in the analysis. Analysis was performed using 
SPSS software (SPSS Inc., Chicago, Illinois, U.S.A.).
124
7.3 Results
The characteristics of patients with inoperable NSCLC are shown in Table 7.1. The 
majority of patients were male and were over the age of 60 years. Approximately 
50% had stage IV disease and had good performance status. Approximately, 25% 
had low haemoglobin, 40% had an elevated white cell count and 70% had an 
abnormal GPS. Of the 45 patients with a GPS of 1, three patients had 
hypoalbuminaemia. Approximately a quarter of patients received active treatment 
and the remaining patients received supportive treatment.
In all, 68 (72%) patients died during the follow-up period. On univariate analysis, 
only the GPS (p=0.017) was a significant predictor of survival.
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7.4 Discussion
It has been previously shown in Chapters 5 and 6, that an inflammation-based 
prognostic score, the Glasgow Prognostic Score (GPS), was useful in predicting 
survival in patients with inoperable NSCLC. Given that the GPS is simple to 
measure, routinely available and well standardised we wished to prospectively 
examine its value compared with ECOG-ps in patients with inoperable NSCLC 
presenting in another centre. In the present study, the GPS was superior to ECOG-ps 
in predicting survival.
The superior value of the GPS may be in part due to the subjective nature of 
performance status and the fact that ECOG-ps reflects the functional status of the 
patients at a specific point in time, whereas the GPS, based as it is on the presence of 
an ongoing systemic inflammatory response and hypoalbuminaemia, predicts the 
progressive nutritional decline of the patient (McMillan et al., 2001b; Scott et al, 
2002).
In summary, the results of the present study confirm that the GPS is at least 
equivalent to ECOG-ps in predicting the survival of patients with inoperable 
NSCLC. It is an objective measurement which is simple to measure, routinely 
available and well standardised.
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Table 7.1 Clinical characteristics of patients with inoperable NSCLC:
Univariate survival analysis
Patients Survival (months)
87 (100%) Median (95% Cl)
Age <60 yrs 13 (15) 12.2 (2.1-22.3)
>60 yrs 74 (85) 6.9 (4.4-9.5)
Sex: Male 50 (58) 6.3(1.8-10.8)
Female 37 (42) 8.5 (5.7-11.4)
Stage III 43 (49) 8.9 (7.6-10.1)
IV 44 (51) 5.3 (2.8-7.8)
Haemoglobin > 12gl_1 65 (75) 8.8 (6.6-11.0)
< 12gr! 22 (25) 3.1 (0.0-6.6)
White Cell Count < 10 xl09/l 52 (60) 8.9 (7.8-10.0)
> 10 xl09/l 35 (40) 4.6 (2.5-6.6)
ECOG-ps 0 9(10) 10.3 (0.0-23.7)
1 33 (38) 6.1 (1.9-10.3)
2 28 (32) 8.7 (6.9-10.3)
3 17(20) 5.2 (0.0-10.8)
GPS 0 26 (30) 9.6 (7.5-11.7)
1 45 (52) 8.5 (5.6-11.5)
2 16(18) 2.2 (0.3-4.2)
Treatment Active 20 (23) 10.3 (7.4-13.1)
Palliative 67 (77) 6.5 (3.9-9.0)
P value
0.497
0.254
0.169
0.084
0.054
0.358
0.017
0.150
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8. PATIENT STUDY: A PROSPECTIVE LONGITUDINAL STUDY OF 
THE SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS 
WITH INOPERABLE NON-SMALL CELL LUNG CANCER
8.1 Introduction
Non-small cell lung cancer (NSCLC) is the most common cause of cancer death in 
North America and Western Europe. Most patients present with advanced inoperable 
disease and the majority die within 12 months.
There is increasing evidence that the progressive nutritional decline of patients with 
advanced cancer is, at least in part, secondary to the presence of a systemic 
inflammatory response. This is consistent with recent work showing that the 
presence of a systemic inflammatory response, as evidenced by an elevated 
circulating concentration of C-reactive protein and reduced concentrations of 
albumin, is associated with poor survival independent of stage and performance 
status in a variety of common solid tumours (O’Gorman et al, 2000; Scott et al,
2002). Furthermore, we have shown that the Glasgow Prognostic score (GPS) has 
prognostic value, independent of performance status, in patients with inoperable 
NSCLC (Chapter 5; Chapter 6; Chapter 7).
Since it appears that an underlying systemic inflammatory response is responsible 
for the progressive nutritional decline of the advanced cancer patient, it might be 
expected that the GPS or its components (i.e. C-reactive protein or albumin) would 
also be useful in the temporal assessment of patients with inoperable NSCLC.
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The aim of the present study was to examine the temporal changes in the GPS 
compared with that of performance status in patients with inoperable NSCLC.
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8.2 Material and Methods
8.2.1 Study Design
Patients presenting with inoperable NSCLC (stage III and IV) to a multi-disciplinary 
clinic at Wishaw General Hospital, Lanarkshire between January 2002 and 
November 2003 were studied prospectively. All patients had cytologically or 
histologically confirmed disease and were staged on the basis of clinical findings, 
chest X-ray and, where appropriate, bronchoscopy, liver ultrasound, isotope bone 
scan and computerised tomography of the thorax, according to the American 
Thoracic Society TNM classification (Mountain, 1991).
Weight, clinical stage, and performance status (Eastern Cooperative Oncology 
Group, ECOG-ps) were recorded at time of diagnosis. Performance status was 
assessed by a respiratory physician. A blood sample was also obtained for 
measurement of white cell count, haemoglobin, albumin and C-reactive protein 
concentrations.
These measurements were also repeated 2- 6 months after diagnosis.
Patients were considered to have undergone active treatment if they received 
chemotherapy (mainly cisplatin based) and / or radical radiotherapy. Patients 
receiving palliative radiotherapy and / or palliative care (symptom control) were 
considered to have had supportive treatment.
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The study was approved by the Research Ethics Committee at Wishaw General 
Hospital, Lanarkshire.
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8.2.2 Methods
Blood parameters, routine laboratory measurements of haemoglobin, white cell 
count, albumin and C-reactive protein concentration were carried out. The 
coefficient of variation for these methods, over the range of measurement, was less 
than 10% as established by routine quality control procedures. The Body Mass 
Index was also calculated by dividing the patient’s weight by the patient’s height in 
meters squared.
The GPS was constructed as previously described (Chapter 5). Briefly, patients with 
both an elevated C-reactive protein (>10mg/l) and hypoalbuminaemia (<35g/l) were 
allocated a score of 2. Patients in whom only one of these biochemical abnormalities 
was present were allocated a score of 1. Patients in whom neither of these 
abnormalities was present were allocated a score of 0.
8.2.3 Statistics
Data are presented as median and range. Where appropriate, comparisons of data 
from different time periods were carried out using the Wilcoxon signed rank test and 
where appropriate the Sign test was applied. Analysis was performed using SPSS 
software (SPSS Inc., Chicago, Illinois, U.S.A.).
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8.3 Results
Ninety one patients with inoperable NSCLC were included in the study. During the 
follow up period 38 patients died without being reassessed and 15 patients were unfit 
to attend the clinic, therefore only 38 patients were available for analysis.
The clinical characteristics of the 38 patients with inoperable NSCLC who had a 
follow-up assessment between 2 - 6  months (median 3.4 months) are shown in Table 
8.1. The majority were male (67%), over the age of 60 years (79%), were stage III 
disease (65%), had good performance status (66%), and white cell count (55%), 
haemoglobin (50%) and albumin (95%) concentration within the normal range. 
Nineteen (50%) of the patients received active treatment. Twenty seven (71%) of 
patients had an elevated GPS. All but 11 of these patients had an elevated C-reactive 
protein concentration. Of the 25 patients with a GPS of 1 no patients had evidence 
of hypoalbuminaemia.
At 2 -  6 months follow-up, no significant differences observed in BMI, haemoglobin 
or white cell count (Table 8.1). In contrast, there was a more significant change in 
ECOG-ps between the two visits. In 16 patients (42%) ECOG-ps deteriorated, while 
it was found to improve in only five patients (13%) (p=0.01).
There was a significant fall in albumin from a median of 39g/l at diagnosis to 37g/l 
at the subsequent clinic visit (p<0.01). Only two patients (5%) were 
hypoalbuminaemic (<35g/l) at the time of the first assessment. However, by the 
time of the second clinic visit, eight patients (21%), including the original two, had
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developed hypoalbuminaemia (p=0.03). There was also a significant increase in C- 
reactive protein concentrations from a median of 19mg/l at diagnosis to 26mg/l at the 
subsequent clinic visit. Overall, a deterioration in GPS was also found (p=0.20). In 
eight patients (21%), the GPS increased between the first and second visit, while in 
four patients (11%) the GPS decreased.
Over the follow-up period there was a significant inverse correlation between the 
change in albumin and the change in C-reactive protein concentrations (rs= -403, 
p=0.009).
135
8.4 Discussion
The present study examined the longitudinal changes in a new inflammation based 
prognostic score (Glasgow Prognostic Score, GPS), and its components and 
performance status (ECOG-ps) in patients with inoperable NSCLC. However, of the 
initial 91 patients studied only 38 patients were available for analysis at 2 to 6 
months. This high attrition rate is consistent with previous longitudinal studies of 
advanced cancer patients (McMillan et al, 1999).
The results showed that, despite there being no alteration in body weight over the 
follow up period, there was a significant fall in albumin concentrations and an 
increase in C-reactive protein concentrations. These results are consistent with the 
hypothesis that the presence of a chronic inflammatory response results in an 
increased demand for specific amino acids and promotes degradation of the body’s 
protein stores including albumin and body cell mass (Preston et al, 1995; McMillan 
et al, 2001b). Despite these changes there was only a trend towards a higher GPS. 
This was due to four patients going from an elevated C-reactive protein (>10mg/l) to 
a normal level (<10mg/l). The reasons for this are unclear. However, it was of 
interest that two patients had just started on steroid therapy prior to their second 
clinic visit.
In contrast ECOG-ps increased over this period. Compared with ECOG-ps, the GPS 
appears to be less sensitive to changes in disease status over time. However, both 
components of the GPS C-reactive protein and albumin did alter over the time 
period. It might be expected that ECOG-ps with four categories would be more
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sensitive to changes in disease status than the GPS with its three categories. Further 
studies are required to examine and refine the GPS, such that in addition to being a 
prognostic tool it may also be used to monitor disease status in patients with 
inoperable NSCLC.
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Table 8.1. Parameters of patients with inoperable NSCLC at diagnosis and 2-6 
months later.
At diagnosis Subsequent Change 2-6 p-valu
(n= 38) clinic visit 2-6 months
months (n= 38)
(n= 38)
Age (years) 69 (45 to 85)
Sex (m / f) 26/12
Treatment
Active / Palliative 19/19
BMI 24.3 (16.7 to 45) 23.8 (14.4 to 44) -0.3 (-3.9 to 2.6) 0.158
Haemoglobin (g/1) 12.2 (8.7 to 17.9) 12.4 (8.5 to 16.1) -1.0 (-4.8 to 3.7) 0.455
White Cell Count (109/1) 9.2 (5.0 to 38.4) 9.0 (6.2 to 19.7) -1.0 (-27.3 to 6.4) 0.940
ECOG (0 /1  / 2 / 3) 1 0 / 15 / 1 0 / 3 6 / 1 3 / 1 1 / 8 5 / 17/16* 0.009
Albumin (g/1) 39 (27 to 45) 37 (25 to 44) -2.0 (-8 to 4) 0.003
C-reactive protein (mg/1) 19(6 to 168) 26 (6 to 314) 7 (-156 to 276) 0.036
GPS ( 0 / 1 / 2 ) 11/ 25 / 2 11 / 20 / 7 4 / 2 6 / 8 * 0.197
*Decreases/ Remains the same/ Increases
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9. Conclusions
9.1 Introduction
In Chapter 1 the aims of this thesis were defined as follows:
1. To examine the relationship between anthropometric parameters, the systemic 
inflammatory response and ECOG-performance status in patients with inoperable 
non-small cell lung cancer
2. To develop and evaluate an inflammation based prognostic score in patients with 
inoperable non-small cell lung cancer.
9.2 General Conclusions
It has long been established that weight loss results in a reduced performance status 
and ultimately leads to death in patients with advanced cancer. Chapter 4 examined 
the reduction in lean body mass in patients with inoperable non-small cell lung 
cancer and found that the observed reduction was associated with a reduced 
performance status and reduced albumin concentrations.
Previous studies have suggested that the reduction in albumin concentrations may be 
linked to the systemic inflammatory response in advanced cancer patients. It has 
also been suggested that combining the inflammatory marker, C-reactive protein, and
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albumin either may be useful prognostic indicator or may allow for the development 
of a useful prognostic tool.
In Chapter 5, this model was tested and it was found that a combined score of C- 
reactive protein and albumin concentration was comparable to ECOG performance 
status in predicting survival in an unselected cohort of inoperable non-small cell lung 
cancer patients.
In Chapter 6, this inflammatory based prognostic score, the Glasgow Prognostic 
Score (GPS), was found to be superior to ECOG-ps in the prediction of survival in 
inoperable NSCLC patients receiving platinum-based chemotherapy.
In Chapter 7, the reproducibility of the GPS was assessed within another centre and 
once more was found to be equivalent to ECOG-ps in the prediction of survival in 
patients with inoperable non-small cell lung cancer.
In Chapter 8, the temporal changes of the GPS and its components were compared to 
that of ECOG-ps in patients with inoperable NSCLC. In this study, when compared 
to ECOG-ps, the GPS appeared to be less sensitive to changes in disease status over 
time. However, the number of patients with follow-up assessments was small and 
further work is required to define the role of the GPS in monitoring patients with 
inoperable NSCLC. Furthermore, it might be expected that ECOG-ps with four 
categories would be more sensitive to changes in disease than GPS with only three 
categories.
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Nevertheless, the GPS appears to be a useful prognostic tool. Part of this is clearly 
related to the detrimental role of nutritional decline in the survival of the advanced 
cancer patient. Indeed, Vigano and co-workers (2000) concluded that the association 
between malnutrition and reduced survival is possibly initially best measured serum 
albumin.
In conclusion, the work presented in this thesis suggests that the Glasgow Prognostic 
Score may be useful in the assessment of patients with inoperable non-small cell 
lung cancer. Further work should be carried out to assess its value in other advanced 
cancers.
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